



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2777700 A1 2011/04/21

(21) **2 777 700**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2010/10/14
(87) Date publication PCT/PCT Publication Date: 2011/04/21
(85) Entrée phase nationale/National Entry: 2012/04/13
(86) N° demande PCT/PCT Application No.: US 2010/052762
(87) N° publication PCT/PCT Publication No.: 2011/047215
(30) Priorité/Priority: 2009/10/14 (US61/251,709)

(51) Cl.Int./Int.Cl. *C07K 2/00* (2006.01),
A61K 38/10 (2006.01), *A61K 38/17* (2006.01),
C07K 1/107 (2006.01), *C07K 14/00* (2006.01),
C07K 7/00 (2006.01)

(71) Demandeur/Applicant:
AILERON THERAPEUTICS, INC., US

(72) Inventeurs/Inventors:
NASH, HUW M., US;
ANNIS, DAVID ALLEN, US;
GUERLAVAIS, VINCENT, US;
LICKLIDER, LAWRENCE, US

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : **MACROCYCLES PEPTIDOMIMETIQUES AMELIORES**
(54) Title: **IMPROVED PEPTIDOMIMETIC MACROCYCLES**

(57) **Abrégé/Abstract:**

The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 April 2011 (21.04.2011)

PCT

(10) International Publication Number
WO 2011/047215 A1

(51) International Patent Classification:
A61K 38/12 (2006.01)

(21) International Application Number:
PCT/US2010/052762

(22) International Filing Date:
14 October 2010 (14.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/251,709 14 October 2009 (14.10.2009) US

(71) Applicant (*for all designated States except US*):
AILERON THERAPEUTICS, INC. [US/US]; 840
Memorial Drive, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **NASH, Huw, M.**
[US/US]; 79 Ledge Rock Road, Concord, MA 01742
(US). **ANNIS, David, Allen** [US/US]; 508 Green Street,
No. 3, Cambridge, MA 02139 (US). **GUERLAVAIS,**
Vincent [FR/US]; 43 Kenilworth Road, Arlington, MA
02476 (US). **LICKLIDER, Lawrence** [US/US]; 17
Wilde Road, Waban, MA 02468 (US).

(74) Agents: **ORBAI, Lucian** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, CA
94304-1050 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: IMPROVED PEPTIDOMIMETIC MACROCYCLES

(57) Abstract: The present invention provides biologically active peptidomimetic macrocycles with improved properties, such as protease resistance, relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.



WO 2011/047215 A1

IMPROVED PEPTIDOMIMETIC MACROCYCLES

CROSS REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 61/251,709, filed October 14, 2009, which is incorporated herein in its entirety by reference.

BACKGROUND OF THE INVENTION

[0002] Peptides are becoming increasingly important in pharmaceutical applications. Unmodified peptides often suffer from poor metabolic stability, poor cell penetrability, and promiscuous binding due to conformational flexibility. To improve these properties, researchers have generated cyclic peptides and peptidomimetics by a variety of methods, including disulfide bond formation, amide bond formation, and carbon-carbon bond formation (Jackson *et al.* (1991), *J. Am. Chem. Soc.* 113:9391-9392; Phelan *et al.* (1997), *J. Am. Chem. Soc.* 119:455-460; Taylor (2002), *Biopolymers* 66: 49-75; Brunel *et al.* (2005), *Chem. Commun.* (20):2552-2554; Hiroshige *et al.* (1995), *J. Am. Chem. Soc.* 117: 11590-11591; Blackwell *et al.* (1998), *Angew. Chem. Int. Ed.* 37:3281-3284; Schafmeister *et al.* (2000), *J. Am. Chem. Soc.* 122:5891-5892). Limitations of these methods include poor metabolic stability (disulfide and amide bonds), poor cell penetrability (disulfide and amide bonds), and the use of potentially toxic metals (for carbon-carbon bond formation). Thus, there is a significant need for improved methods to produce peptides or peptidomimetics that possess improved biological properties such as protease stability. The present invention addresses these and other needs in the art.

SUMMARY OF THE INVENTION

[0003] The present invention provides biologically active peptidomimetic macrocycles with improved protease stability relative to a corresponding crosslinked polypeptide.

[0004] In one embodiment, the present invention provides a method of preparing a polypeptide with optimized protease stability, the method comprising: (a) providing a parent polypeptide comprising a cross-linker connecting a first amino acid and a second amino acid of said polypeptide; (b) identifying a first motif comprising a protease cleavage site within said polypeptide; (c) replacing the first motif with a second motif comprising at least one α,α -disubstituted amino acid, thereby producing a modified polypeptide; (d) measuring the proteolytic stability of the modified polypeptide; and (e) selecting the modified polypeptide as a polypeptide with optimized protease stability if the modified polypeptide has higher proteolytic stability than the parent polypeptide.

[0005] In another embodiment, the crosslinked polypeptide comprises an α -helical domain of a BCL-2 family member. For example, the crosslinked polypeptide comprises a BH3 domain. In other embodiments, the crosslinked polypeptide comprises at least 60%, 70%, 80%, 85%, 90% or 95% of any of the sequences in Tables 1, 2, 3 and 4.

[0006] In still other embodiments, the improved protease stability results in increased intracellular stability, increased extracellular stability, increased stability in blood, increased stability in the mouth or digestive tract, increased stability in the lungs, increased stability in the nasal sinus, increased stability in the eye, or increased stability in the skin.

[0007] In other embodiments, the crosslinker connects two α -carbon atoms. In still other embodiments, the crosslinked polypeptide comprises an alpha-helix.

[0008] In one embodiment, the first motif is identified outside the sequence spanned by the cross-linker connecting said first and second amino acids. In another embodiment, the parent polypeptide comprises a helix, such as an α -helix. In yet another embodiment, the cross-linker connects the alpha-carbons (or side chains) of said first amino acid and said second amino acid.

[0009] In one embodiment, the cross-linker connects a first amino acid and a second amino acid that are separated by three amino acids. For example, the cross-linker comprises between 6 and 14 consecutive bonds, or between 8 and 12 consecutive bonds. In another embodiment, the parent polypeptide comprises a macrocycle of about 18 atoms to 26 atoms.

[0010] In another embodiment, the cross-linker connects a first amino acid and a second amino acid that are separated by six amino acids. For example, the cross-linker comprises between 8 and 16 consecutive bonds, or between 10 and 13 consecutive bonds. In another embodiment, the parent polypeptide comprises a macrocycle of about 29 atoms to 37 atoms.

[0011] In yet another embodiment, the cross-linker spans from 1 turn to 5 turns of the alpha-helix. For example, the cross-linker spans 1 or 2 turns of the alpha helix. In one embodiment, the length of the cross-linker is about 5 Å to about 9 Å per turn of the alpha-helix.

[0012] In various embodiments, the parent polypeptide carries a net positive charge at pH 7.4. In other embodiments, the parent polypeptide comprises one or more of a halogen, alkyl group, a fluorescent moiety, affinity label, targeting moiety, or a radioisotope. In one embodiment, at least one of the first and second amino acids connected by said cross-linker is an α,α -disubstituted amino acid. For example, both the first and second amino acids connected by said cross-linker are α,α -disubstituted.

[0013] In one embodiment, the protease is an intracellular or extracellular protease. For example, the protease is present in the blood, mouth, digestive tract, lungs, nasal sinus, skin, or eye of a vertebrate. In another embodiment, the optimized polypeptide provides a therapeutic effect and/or binds to an intracellular target.

[0014] The invention also provides a method of treating or controlling a disorder associated with aberrant BCL-2 family member expression or activity, comprising administering an effective amount of a polypeptide according to any of the preceding claims to a subject in need thereof.

[0015] Also provided is a method of treating or controlling a hyperproliferative disease or condition mediated by the interaction or binding between p53 and hDM2 in hyperproliferative cells, comprising administering an effective amount of a polypeptide according to any of the preceding claims to a subject in need thereof.

[0016] In another aspect, the invention relates to the use of a polypeptide of the invention in the manufacture of a medicament for treating or controlling a disorder associated with aberrant BCL-2 family member expression or activity, or for treating or controlling a hyperproliferative disease or condition mediated by the interaction or binding between p53 and hDM2 in hyperproliferative cells.

[0017] In some embodiments, an α -carbon atom of an amino acid that is present within the second motif of said modified polypeptide is substituted with a moiety of formula R-, wherein R- is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. In one embodiment, R- is alkyl. For example, R- is methyl. Alternatively, R- and any portion of the crosslinker taken together can form a cyclic structure. In another embodiment, the crosslinker is formed of consecutive carbon-carbon bonds. For example, the crosslinker may comprise at least 8, 9, 10, 11, or 12 consecutive bonds. In other embodiments, the crosslinker may comprise at least 7, 8, 9, 10, or 11 carbon atoms.

[0018] In other embodiments, the protease stability of the modified polypeptide is improved at least 2-fold relative to the parent polypeptide. For example, the protease stability of said polypeptide is improved at least 5-fold, 10-fold, or 15-fold.

INCORPORATION BY REFERENCE

[0019] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0021] FIGURE 1 illustrates the possible proteolysis products of the SP-1 peptidomimetic macrocycle.

[0022] FIGURE 2 shows the sequence for the SP-1 peptidomimetic macrocycle along with the numbers corresponding to each proteolysis products.

[0023] FIGURE 3 illustrates the proteolysis products of the SP-1 peptidomimetic macrocycle as determined by ion mobility-MS and MS-MS analysis when treated with the intracellular protease Cathepsin D.

[0024] FIGURE 4 illustrates the proteolysis products of the SP-1 peptidomimetic macrocycle as determined by ion mobility-MS and MS-MS analysis when treated with the intracellular protease Cathepsin B.

[0025] FIGURE 5 illustrates the proteolysis products of the SP-1 peptidomimetic macrocycle as determined by ion mobility-MS and MS-MS analysis when treated with the intracellular protease Cathepsin L.

[0026] FIGURE 6 illustrates the increase in stability to the intracellular protease Cathepsin D for peptidomimetic macrocycles of the invention.

[0027] FIGURE 7 illustrates the increase in stability to the intracellular protease Cathepsin D for peptidomimetic macrocycles of the invention.

[0028] FIGURE 8 illustrates the increase in stability in a HeLa cell assay for peptidomimetic macrocycles of the invention.

[0029] FIGURE 9 illustrate the proteolysis products of the SP-1 peptidomimetic macrocycle as determined by ion mobility-MS and MS-MS analysis when treated with rat gastrointestinal mucosal peptidases.

[0030] FIGURES 10, 11 and 12 illustrate the increase in stability to rat gastrointestinal mucosal peptidases for peptidomimetic macrocycles of the invention.

[0031] FIGURES 13 and 14 illustrate the increase in stability to gut protease pepsin of peptidomimetic macrocycles of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0032] As used herein, the terms "treating" and "to treat", mean to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms. The term "treatment" includes alleviation, elimination of causation (temporary or permanent) of, or prevention of symptoms and disorders associated with any condition. The treatment may be a pre-treatment as well as a treatment at the onset of symptoms.

[0033] The term "standard method of care" refers to any therapeutic or diagnostic method, compound, or practice which is part of the standard of care for a particular indication. The "standard of care" may be established by any authority such as a health care provider or a national or regional institute for any diagnostic or treatment process that a clinician should follow for a certain type of patient, illness, or clinical circumstance. Exemplary standard of care methods for various type of cancers are provided for instance by the the National Cancer Institute.

[0034] As used herein, the term “cell proliferative disorder” encompasses cancer, hyperproliferative disorders, neoplastic disorders, immunoproliferative disorders and other disorders. A “cell proliferative disorder” relates to cells having the capacity for autonomous growth, *i.e.*, an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, *i.e.*, characterizing or constituting a disease state, or may be categorized as non-pathologic, *i.e.*, a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of breast, lung, liver, colon and ovarian origin. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth and immunoproliferative diseases. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair. Examples of cellular proliferative and/or differentiative disorders include cancer, *e.g.*, carcinoma, sarcoma, or metastatic disorders.

[0035] The term “derived from” in the context of the relationship between a cell line and a related cancer signifies that the cell line may be established from any cancer in a specific broad category of cancers.

[0036] As used herein, the term “macrocycle” refers to a molecule having a chemical structure including a ring or cycle formed by at least 9 covalently bonded atoms.

[0037] As used herein, the term “peptidomimetic macrocycle”, “crosslinked polypeptide” or “stapled peptide” refers to a compound comprising a plurality of amino acid residues joined by a plurality of peptide bonds and at least one macrocycle-forming linker which forms a macrocycle between a first naturally-occurring or non-naturally-occurring amino acid residue (or analog) and a second naturally-occurring or non-naturally-occurring amino acid residue (or analog) within the same molecule. Peptidomimetic macrocycles include embodiments where the macrocycle-forming linker connects the α carbon of the first amino acid residue (or analog) to the α carbon of the second amino acid residue (or analog). The peptidomimetic macrocycles optionally include one or more non-peptide bonds between one or more amino acid residues and/or amino acid analog residues, and optionally include one or more non-naturally-occurring amino acid residues or amino acid analog residues in addition to any which form the macrocycle.

[0038] Unless otherwise stated, compounds and structures referred to herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures wherein hydrogen is replaced by deuterium or tritium, or wherein carbon atom is replaced by ^{13}C - or ^{14}C -enriched carbon, or wherein a carbon atom is replaced by silicon, are within the scope of this invention. The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0039] As used herein, the term “stability” refers to the maintenance of a defined secondary structure in solution by a peptidomimetic macrocycle of the invention as measured by circular dichroism, NMR or another biophysical measure, or resistance to proteolytic degradation *in vitro* or *in vivo*. Non-limiting examples of secondary structures contemplated in this invention are α -helices, β -turns, and β -pleated sheets.

[0040] As used herein, the term “helical stability” refers to the maintenance of α helical structure by a peptidomimetic macrocycle of the invention as measured by circular dichroism or NMR. For example, in some embodiments, the peptidomimetic macrocycles of the invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in α -helicity as determined by circular dichroism compared to a corresponding macrocycle lacking the R- substituent.

[0041] The term " α -amino acid" or simply "amino acid" refers to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the α -carbon. Suitable amino acids include, without limitation, both the D- and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by organic synthesis or other metabolic routes. Unless the context specifically indicates otherwise, the term amino acid, as used herein, is intended to include amino acid analogs.

[0042] The term "naturally occurring amino acid" refers to any one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V.

[0043] The term "amino acid analog" or "non-natural amino acid" refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptidomimetic macrocycle. Amino acid analogs include, without limitation, compounds which are structurally identical to an amino acid, as defined herein, except for the inclusion of one or more additional methylene groups between the amino and carboxyl group (*e.g.*, α -amino β -carboxy acids), or for the substitution of the amino or carboxy group by a similarly reactive group (*e.g.*, substitution of the primary amine with a secondary or tertiary amine, or substitution of the carboxy group with an ester).

[0044] A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide (*e.g.*, a BH3 domain or the p53 MDM2 binding domain) without abolishing or substantially altering its essential biological or biochemical activity (*e.g.*, receptor binding or activation). An "essential" amino acid residue is a residue that, when altered from the wild-type sequence of the polypeptide, results in abolishing or substantially abolishing the polypeptide's essential biological or biochemical activity.

[0045] A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, K, R, H), acidic side chains (*e.g.*, D, E), uncharged polar side chains (*e.g.*, G, N, Q, S, T, Y, C), nonpolar side chains (*e.g.*, A, V, L, I, P, F, M, W), beta-branched side chains (*e.g.*, T, V, I) and aromatic side chains (*e.g.*, Y, F, W, H). Thus, a predicted nonessential amino acid residue in a BH3 polypeptide, for example, is preferably replaced with another amino acid residue from the same side chain family. Other examples of acceptable substitutions are substitutions based on isosteric considerations (*e.g.* norleucine for methionine) or other properties (*e.g.* 2-thienylalanine for phenylalanine).

[0046] The term "member" as used herein in conjunction with macrocycles or macrocycle-forming linkers refers to the atoms that form or can form the macrocycle, and excludes substituent or side chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane and 1,3-dimethyl cyclodecane are all considered ten-membered macrocycles as the hydrogen or fluoro substituents or methyl side chains do not participate in forming the macrocycle.

[0047] The symbol " " when used as part of a molecular structure refers to a single bond or a *trans* or *cis* double bond.

[0048] The term "amino acid side chain" refers to a moiety attached to the α -carbon in an amino acid. For example, the amino acid side chain for alanine is methyl, the amino acid side chain for phenylalanine is phenylmethyl, the amino acid side chain for cysteine is thiomethyl, the amino acid side chain for aspartate is carboxymethyl, the amino acid side chain for tyrosine is 4-hydroxyphenylmethyl, etc. Other non-naturally occurring amino acid side chains are also included, for example, those that occur in nature (*e.g.*, an amino acid metabolite) or those that are made synthetically (*e.g.*, an α,α di-substituted amino acid).

[0049] The term " α,α -disubstituted amino" acid refers to a molecule or moiety containing both an amino group and a carboxyl group bound to a carbon (the α -carbon) that is attached to two natural or non-natural amino acid side chains.

[0050] The term "polypeptide" encompasses two or more naturally or non-naturally-occurring amino acids joined by a covalent bond (*e.g.*, an amide bond). Polypeptides as described herein include full length proteins (*e.g.*, fully processed proteins) as well as shorter amino acid sequences (*e.g.*, fragments of naturally-occurring proteins or synthetic polypeptide fragments).

[0051] The term "macrocyclization reagent" or "macrocycle-forming reagent" as used herein refers to any reagent which may be used to prepare a peptidomimetic macrocycle of the invention by mediating the reaction between two reactive groups. Reactive groups may be, for example, an azide and alkyne, in which case macrocyclization reagents include, without limitation, Cu reagents such as reagents which provide a reactive Cu(I) species, such as CuBr, CuI or CuOTf, as well as Cu(II) salts such as Cu(CO₂CH₃)₂, CuSO₄, and CuCl₂ that can be converted in situ to an active Cu(I) reagent by the addition of a reducing agent such as ascorbic acid or sodium ascorbate. Macrocyclization reagents may additionally include, for example, Ru reagents known in the art such as Cp*RuCl(PPh₃)₂, [Cp*RuCl]₄ or other Ru reagents which may provide a reactive Ru(II) species. In other cases, the reactive groups are terminal olefins. In such embodiments, the macrocyclization reagents or macrocycle-forming reagents are metathesis catalysts including, but not limited to, stabilized, late transition metal carbene complex catalysts such as Group VIII transition metal carbene catalysts. For example, such catalysts are Ru and Os metal centers having a +2 oxidation state, an electron count of 16 and pentacoordinated. Additional catalysts are disclosed in Grubbs et al., "Ring Closing Metathesis and Related Processes in Organic Synthesis" Acc. Chem. Res. 1995, 28, 446-452, and U.S. Pat. No. 5,811,515. In yet other cases, the reactive groups are thiol groups. In such embodiments, the macrocyclization reagent is, for example, a linker functionalized with two thiol-reactive groups such as halogen groups.

[0052] The term "halo" or "halogen" refers to fluorine, chlorine, bromine or iodine or a radical thereof.

[0053] The term "alkyl" refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C₁-C₁₀ indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, "alkyl" is a chain (straight or branched) having 1 to 20 (inclusive) carbon atoms in it.

[0054] The term "alkylene" refers to a divalent alkyl (*i.e.*, -R-).

[0055] The term "alkenyl" refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C₂-C₁₀ indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term "lower alkenyl" refers to a C₂-C₆ alkenyl chain. In the absence of any numerical designation, "alkenyl" is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.

[0056] The term "alkynyl" refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C₂-C₁₀ indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term "lower alkynyl" refers to a C₂-C₆ alkynyl chain. In the absence of any numerical designation, "alkynyl" is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.

[0057] The term "aryl" refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of aryl groups include phenyl, naphthyl and the like. The term "arylalkyl" or the term "aralkyl" refers to alkyl substituted with an aryl. The term "arylalkoxy" refers to an alkoxy substituted with aryl.

[0058] "Arylalkyl" refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with a C₁-C₅ alkyl group, as defined above. Representative examples of an arylalkyl group include, but are not

limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-propylphenyl, 3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3-butylphenyl, 4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-isobutylphenyl, 3-isobutylphenyl, 4-isobutylphenyl, 2-sec-butylphenyl, 3-sec-butylphenyl, 4-sec-butylphenyl, 2-t-butylphenyl, 3-t-butylphenyl and 4-t-butylphenyl.

[0059] "Arylamido" refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more -C(O)NH₂ groups. Representative examples of an arylamido group include 2-C(O)NH₂-phenyl, 3-C(O)NH₂-phenyl, 4-C(O)NH₂-phenyl, 2-C(O)NH₂-pyridyl, 3-C(O)NH₂-pyridyl, and 4-C(O)NH₂-pyridyl,

[0060] "Alkylheterocycle" refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a heterocycle. Representative examples of an alkylheterocycle group include, but are not limited to, -CH₂CH₂-morpholine, -CH₂CH₂-piperidine, -CH₂CH₂CH₂-morpholine, and -CH₂CH₂CH₂-imidazole.

[0061] "Alkylamido" refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a -C(O)NH₂ group. Representative examples of an alkylamido group include, but are not limited to, -CH₂-C(O)NH₂, -CH₂CH₂-C(O)NH₂, -CH₂CH₂CH₂-C(O)NH₂, -CH₂CH₂CH₂CH₂-C(O)NH₂, -CH₂CH₂CH₂CH₂CH₂-C(O)NH₂, -CH₂CH(C(O)NH₂)CH₃, -CH₂CH(C(O)NH₂)CH₂CH₃, -CH(C(O)NH₂)CH₂CH₃, -C(CH₃)₂CH₂-C(O)NH₂, -CH₂-CH₂-NH-C(O)-CH₃, -CH₂-CH₂-NH-C(O)-CH₃-CH₃, and -CH₂-CH₂-NH-C(O)-CH=CH₂.

[0062] "Alkanol" refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a hydroxyl group. Representative examples of an alkanol group include, but are not limited to, -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, -CH₂CH(OH)CH₃, -CH₂CH(OH)CH₂CH₃, -CH(OH)CH₃ and -C(CH₃)₂CH₂OH.

[0063] "Alkylcarboxy" refers to a C₁-C₅ alkyl group, as defined above, wherein one of the C₁-C₅ alkyl group's hydrogen atoms has been replaced with a --COOH group. Representative examples of an alkylcarboxy group include, but are not limited to, -CH₂COOH, -CH₂CH₂COOH, -CH₂CH₂CH₂COOH, -CH₂CH₂CH₂CH₂COOH, -CH₂CH(COOH)CH₃, -CH₂CH₂CH₂CH₂CH₂COOH, -CH₂CH(COOH)CH₂CH₃, -CH(COOH)CH₂CH₃ and -C(CH₃)₂CH₂COOH.

[0064] The term "cycloalkyl" as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted. Some cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0065] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (*e.g.*, carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.

[0066] The term "heteroarylalkyl" or the term "heteroaralkyl" refers to an alkyl substituted with a heteroaryl. The term "heteroarylalkoxy" refers to an alkoxy substituted with heteroaryl.

[0067] The term "heteroarylalkyl" or the term "heteroaralkyl" refers to an alkyl substituted with a heteroaryl. The term "heteroarylalkoxy" refers to an alkoxy substituted with heteroaryl.

[0068] The term "heterocyclyl" refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (*e.g.*, carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring are substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.

[0069] The term "substituent" refers to a group replacing a second atom or group such as a hydrogen atom on any molecule, compound or moiety. Suitable substituents include, without limitation, halo, hydroxy, mercapto, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, amino, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, and cyano groups.

[0070] In some embodiments, the compounds of this invention contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are included in the present invention unless expressly provided otherwise. In some embodiments, the compounds of this invention are also represented in multiple tautomeric forms, in such instances, the invention includes all tautomeric forms of the compounds described herein (*e.g.*, if alkylation of a ring system results in alkylation at multiple sites, the invention includes all such reaction products). All such isomeric forms of such compounds are included in the present invention unless expressly provided otherwise. All crystal forms of the compounds described herein are included in the present invention unless expressly provided otherwise.

[0071] As used herein, the terms "increase" and "decrease" mean, respectively, to cause a statistically significantly (*i.e.*, $p < 0.1$) increase or decrease of at least 5%.

[0072] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable is equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable is equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 takes the values 0, 1 or 2 if the variable is inherently discrete, and takes the values 0.0, 0.1, 0.01, 0.001, or any other real values ≥ 0 and ≤ 2 if the variable is inherently continuous.

[0073] As used herein, unless specifically indicated otherwise, the word "or" is used in the inclusive sense of "and/or" and not the exclusive sense of "either/or."

[0074] The term "on average" represents the mean value derived from performing at least three independent replicates for each data point.

[0075] The term "protease stability" encompasses structural and functional properties of a macrocycle of the invention. Protease stability is, for example, structural stability, alpha-helicity, affinity for a target, resistance to proteolytic degradation, cell penetrability, intracellular stability, *in vivo* stability, or any combination thereof.

[0076] The details of one or more particular embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

Design of the Peptidomimetic Macrocycles of the Invention

[0077] Any protein or polypeptide with a known primary amino acid sequence which contains a specific or nonspecific protease cleavage site is the subject of the present invention. For example, the sequence of the parent

polypeptide can be analyzed with software that compares the sequence with a database of all known protease cleavage recognition motifs (for example, using Swiss-Prot). Alternatively, sites of proteolysis are determined by incubation of the parent polypeptide with purified protease or a biological extract or tissue that contains proteases, followed by analysis of the resulting proteolysis products by a technique such as ion mobility mass spectrometry or MS/MS sequencing. Such testing can also be done in vivo administration of the polypeptide and analysis of the resulting cleavage products, and in one embodiment can utilize radiolabeled polypeptide. By such determinations, the appropriate amino acids are substituted with the amino acids analogs of the invention.

[0078] Any known protease can be the subject of the present invention, including mammalian (e.g. human) proteases. Various proteases/peptidases are known in the art along with their specific or nonspecific cleavage sites. Such proteases (and their cleavage properties) include, for example, Aminopeptidase M (hydrolysis from N-terminus); Calpain 1, 11, 5, 9, S1, S2; Carboxypeptidase Y (hydrolysis from C-terminus); Caspase 1, 4, 5 (W/LEHD-X); Caspase 2, 3, 7 (DEXD-X); Caspase 6, 8, 9 (L/VEXD-X); Cathepsins B, D, E, G, K, L, O, S, or W; Cystatin 8, A, B, C, D, E/M, F, S, SA, or SN; Dipeptidylpeptidase 7 (DPP7, DPPVII); Chymotrypsin (Y-X, F-X, T-X, L-X, M-X, A-X, E-X); Elastase; Furin; HtrA2 (HtrA serine peptidase 2); Plasmin; Plasminogen (PLG); PMPCB (peptidase (mitochondrial processing) beta); Prekallikrein; Trypsin; Factor Xa (I-E/D-G-R); Factors XIa, XIIa, IX a (R); Kallikrein (R/K); Protein C (R); Thrombin (P4-P3-P-R/K*P1'-P2'-P3/P4 hydrophobic; P1'/ P2' non-acidic; P2-R/K*P1' P2 or P1' are G); and Pepsin (F-Z, M-Z, L-Z, W-Z digestion where Z is a hydrophobic residue, but will also cleave others). Additional proteases and their cleavage properties are known to persons skilled in the art, and are described, for example, in Thornberry et al., A combinatorial approach defines specificities of members of the caspase family and granzyme B, *Journal of Biological Chemistry* 272 17907-17911. Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase, Parks, T. D., Keuther, K. K., Howard, E. D., Johnston, S. A. & Dougherty, W. G., *Analytical Biochemistry* (1994) 216 413-417; Life Technologies Ltd; Keil, B. Specificity of proteolysis. Springer-Verlag Berlin-Heidelberg-NewYork, pp.335. (1992); Laszlo Polgar, *Mechanisms of Protease Action* (1989), CRC Press, Boca Raton; Allen J. Barrett, Neil D. Rawlings, J. F. Woessner, *Handbook of Proteolytic Enzymes* (2004), Elsevier/Academic Press.

[0079] After the motif comprising a protease cleavage site has been determined within the sequence of the parent crosslinked polypeptide, the motif is replaced with a second motif in order to optimize the protease stability of the resulting modified polypeptide. In one embodiment, the motif comprising the protease cleavage site is replaced with a second motif comprising at least one α,α -disubstituted amino acid, such as 2-aminoisobutyric acid or as described herein. In other embodiments, within the parent polypeptide comprising a first and second crosslinked amino acids, the motif comprising a protease cleavage site is replaced with a motif comprising a third amino acid which is connected by a second crosslinker to another amino acid within the polypeptide. For example, the crosslinker can connect the third amino acid to either the first or second amino acids, such that the resulting polypeptide comprises an amino acid which is connected by two crosslinkers to two other amino acids ("stitched" polypeptides). Alternatively, the crosslinker can connect the third amino acid to a fourth amino acid which is distinct from either the first or second amino acids, such that the resulting polypeptide comprises two crosslinkers which do not have an amino acid in common.

[0080] In some embodiments of the invention, the peptide sequence is derived from the BCL-2 family of proteins. The BCL-2 family is defined by the presence of up to four conserved BCL-2 homology (BH) domains designated BH1, BH2, BH3, and BH4, all of which include α -helical segments (Chittenden *et al.* (1995), *EMBO* 14:5589; Wang *et al.* (1996), *Genes Dev.* 10:2859). Anti-apoptotic proteins, such as BCL-2 and BCL-X_L, display sequence conservation in all BH domains. Pro-apoptotic proteins are divided into "multidomain" family members (e.g., BAK, BAX), which possess homology in the BH1, BH2, and BH3 domains, and "BH3-domain only" family members (e.g., BID, BAD, BIM, BIK,

NOXA, PUMA), that contain sequence homology exclusively in the BH3 amphipathic α -helical segment. BCL-2 family members have the capacity to form homo- and heterodimers, suggesting that competitive binding and the ratio between pro- and anti-apoptotic protein levels dictates susceptibility to death stimuli. Anti-apoptotic proteins function to protect cells from pro-apoptotic excess, *i.e.*, excessive programmed cell death. Additional "security" measures include regulating transcription of pro-apoptotic proteins and maintaining them as inactive conformers, requiring either proteolytic activation, dephosphorylation, or ligand-induced conformational change to activate pro-death functions. In certain cell types, death signals received at the plasma membrane trigger apoptosis via a mitochondrial pathway. The mitochondria can serve as a gatekeeper of cell death by sequestering cytochrome c, a critical component of a cytosolic complex which activates caspase 9, leading to fatal downstream proteolytic events. Multidomain proteins such as BCL-2/BCL-X_L and BAK/BAX play dueling roles of guardian and executioner at the mitochondrial membrane, with their activities further regulated by upstream BH3-only members of the BCL-2 family. For example, BID is a member of the BH3-domain only family of pro-apoptotic proteins, and transmits death signals received at the plasma membrane to effector pro-apoptotic proteins at the mitochondrial membrane. BID has the capability of interacting with both pro- and anti-apoptotic proteins, and upon activation by caspase 8, triggers cytochrome c release and mitochondrial apoptosis. Deletion and mutagenesis studies determined that the amphipathic α -helical BH3 segment of pro-apoptotic family members may function as a death domain and thus may represent a critical structural motif for interacting with multidomain apoptotic proteins. Structural studies have shown that the BH3 helix can interact with anti-apoptotic proteins by inserting into a hydrophobic groove formed by the interface of BH1, 2 and 3 domains. Activated BID can be bound and sequestered by anti-apoptotic proteins (*e.g.*, BCL-2 and BCL-X_L) and can trigger activation of the pro-apoptotic proteins BAX and BAK, leading to cytochrome c release and a mitochondrial apoptosis program. BAD is also a BH3-domain only pro-apoptotic family member whose expression triggers the activation of BAX/BAK. In contrast to BID, however, BAD displays preferential binding to anti-apoptotic family members, BCL-2 and BCL-X_L. Whereas the BAD BH3 domain exhibits high affinity binding to BCL-2, BAD BH3 peptide is unable to activate cytochrome c release from mitochondria *in vitro*, suggesting that BAD is not a direct activator of BAX/BAK. Mitochondria that over-express BCL-2 are resistant to BID-induced cytochrome c release, but co-treatment with BAD can restore BID sensitivity. Induction of mitochondrial apoptosis by BAD appears to result from either: (1) displacement of BAX/BAK activators, such as BID and BID-like proteins, from the BCL-2/BCL-XL binding pocket, or (2) selective occupation of the BCL-2/BCL-XL binding pocket by BAD to prevent sequestration of BID-like proteins by anti-apoptotic proteins. Thus, two classes of BH3-domain only proteins have emerged, BID-like proteins that directly activate mitochondrial apoptosis, and BAD-like proteins, that have the capacity to sensitize mitochondria to BID-like pro-apoptotics by occupying the binding pockets of multidomain anti-apoptotic proteins. Various α -helical domains of BCL-2 family member proteins amenable to the methodology disclosed herein have been disclosed (Walensky *et al.* (2004), *Science* 305:1466; and Walensky *et al.*, U.S. Patent Publication No. 2005/0250680, the entire disclosures of which are incorporated herein by reference).

[0081] In other embodiments, the peptide sequence is derived from the tumor suppressor p53 protein which binds to the oncogene protein MDM2. The MDM2 binding site is localized within a region of the p53 tumor suppressor that forms an α helix. In U.S. Pat. No. 7,083,983, the entire contents of which are incorporated herein by reference, Lane *et al.* disclose that the region of p53 responsible for binding to MDM2 is represented approximately by amino acids 13-31 (PLSQETFSDLWKLLPENNV) of mature human P53 protein. Other modified sequences disclosed by Lane are also contemplated in the instant invention. Furthermore, the interaction of p53 and MDM2 has been discussed by Shair *et al.* (1997), *Chem. & Biol.* 4:791, the entire contents of which are incorporated herein by reference, and mutations in the p53

gene have been identified in virtually half of all reported cancer cases. As stresses are imposed on a cell, p53 is believed to orchestrate a response that leads to either cell-cycle arrest and DNA repair, or programmed cell death. As well as mutations in the p53 gene that alter the function of the p53 protein directly, p53 can be altered by changes in MDM2. The MDM2 protein has been shown to bind to p53 and disrupt transcriptional activation by associating with the transactivation domain of p53. For example, an 11 amino-acid peptide derived from the transactivation domain of p53 forms an amphipathic α -helix of 2.5 turns that inserts into the MDM2 crevice. Thus, in some embodiments, novel α -helix structures generated by the method of the present invention are engineered to generate structures that bind tightly to the helix acceptor and disrupt native protein-protein interactions. These structures are then screened using high throughput techniques to identify optimal small molecule peptides. The novel structures that disrupt the MDM2 interaction are useful for many applications, including, but not limited to, control of soft tissue sarcomas (which over-expresses MDM2 in the presence of wild type p53). These cancers are then, in some embodiments, held in check with small molecules that intercept MDM2, thereby preventing suppression of p53. Additionally, in some embodiments, small molecule disrupters of MDM2-p53 interactions are used as adjuvant therapy to help control and modulate the extent of the p53 dependent apoptosis response in conventional chemotherapy.

[0082] A non-limiting exemplary list of suitable peptide sequences for use in the present invention is given below:

TABLE 1

Name	Sequence (bold = critical residues)	Cross-linked Sequence (<u>X</u> = x-link residue)
BH3 peptides		
BID-BH3	QEDIIRNIARHLA QVGD SMDSIPP	QEDIIRNIARHLA <u>XVGD</u> SMDSIPP
BIM-BH3	DNRPEIWIAQELRRIG DEF NAYYAR	DNRPEIWIAQELR <u>XIGD</u> FNAYYAR
BAD-BH3	NLWAAQRYGRELRRMS DEF VDSFKK	NLWAAQRYGRELR <u>XMSD</u> FVDSFKK
PUMA-BH3	EEQWAREIGAQLRRMADD LNA QYER	EEQWAREIGAQLR <u>XMAD</u> LNAYYER
Hrk-BH3	RSSAAQLTAAR LKALG DELHQRTM	RSSAAQLTAARL <u>KXLGD</u> XLHQRTM
NOXAA-BH3	AELPPEFAAQLRKIG DKV YCTW	AELPPEFAAQLR <u>XIGD</u> XVYCTW
NOXAB-BH3	VPADLKDECAQLRRIG DKV NLRQKL	VPADLKDECAQLR <u>XIGD</u> XVNLQKL
BMF-BH3	QHRAEVQIARKLQCI ADQ FHRLHT	QHRAEVQIARKLQ <u>XIAD</u> XFHRLHT
BLK-BH3	SSAAQLTAAR LKALG DELHQRT	SSAAQLTAARL <u>KXLGD</u> XLHQRT
BIK-BH3	CMEGSDALALRLACIG DEM DVSLRA	CMEGSDALALRLA <u>XIGD</u> XMDVSLRA
Bnip3	DIERRKEVESILK KNSD WIWDWSS	DIERRKEVESILK <u>XNSD</u> XIWDWSS
BOK-BH3	GRLAEVCAVLLRL GDE LEMIRP	GRLAEVCAVLL <u>XLGD</u> XLEMIRP
BAX-BH3	PQDASTKKSECLKRIG DEL DSNMEL	PQDASTKKSECLK <u>XIGD</u> XLDSNMEL
BAK-BH3	PSSTMGQVGRQLAI IGD DINRR	PSSTMGQVGRQLA <u>XIGD</u> XINRR
BCL2L1-BH3	KQALREAG DEF ELR	KQALR <u>XAGD</u> XFELR
BCL2-BH3	LSPPVVHLALALRQAG DDF SRR	LSPPVVHLALALR <u>XAGD</u> XFSSRR
BCL-XL-BH3	EVIPMAAVKQALREAG DEF ELRY	EVIPMAAVKQALR <u>XAGD</u> XFELRY
BCL-W-BH3	PADPLHQAMRAAG DEF ETRF	PADPLHQAMR <u>XAGD</u> XFETRF
MCL1-BH3	ATSRKLETLRRV GDG VQRNHETA	ATSRKLETLR <u>XVGD</u> XVQRNHETA
MTD-BH3	LAEVCTVLLRL GDE LEQIR	LAEVCTVLL <u>XLGD</u> XLEQIR
MAP-1-BH3	MTVGELSRA LGH ENGSLDP	MTVGELSRA <u>LXENG</u> XLDP
NIX-BH3	VVEGEKEVEAL KKSAD WVSDWS	VVEGEKEVEAL <u>KXSAD</u> XVSDWS
4ICD(ERBB4)-BH3	SMARDPQRYLV IQGD DRMKL	SMARDPQRYLV <u>XQGD</u> DRMKL

Table 1 lists human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.

TABLE 2

Name	Sequence (bold = critical residues)	Cross-linked Sequence (<u>X</u> = x-link residue)
BH3 peptides		
BID-BH3	QEDIIRNIARHLA QVGDS MDRSIPP	QEDIIRNI <u>X</u> RHL <u>X</u> Q VGDS MDRSIPP
BIM-BH3	DNRPEIWIAQELRRIG DEFN AYYAR	DNRPEIW <u>X</u> QEL <u>X</u> RIG DEFN AYYAR
BAD-BH3	NLWAAQRYGRELRRMS DEFVDS FKK	NLWAAQRY <u>X</u> REL <u>X</u> RRMS DEFVDS FKK
PUMA-BH3	EEQWAREIGAQLRRMADDLNAQYER	EEQWAREI <u>X</u> AQL <u>X</u> RMADDLNAQYER
Hrk-BH3	RSSAAQLTAARLKAL GDEL HQRTM	RSSAAQLT <u>X</u> ARL <u>X</u> AL GDEL HQRTM
NOXAA-BH3	AELPPEFAAQLRKIG DKVY CTW	AELPPEF <u>X</u> AQL <u>X</u> KIG DKVY CTW
NOXAB-BH3	VPADLKDECAQLRRIG DKVN LRQKL	VPADLKDE <u>X</u> AQL <u>X</u> RIG DKVN LRQKL
BMF-BH3	QHRAEVQIARKLQCIAD QF HRLHT	QHRAEVQI <u>X</u> RKL <u>X</u> CIAD QF HRLHT
BLK-BH3	SSAAQLTAARLKAL GDEL HQRT	SSAAQLT <u>X</u> ARL <u>X</u> AL GDEL HQRT
BIK-BH3	CMEGSDALALRLACIG DEMDV SLRA	CMEGSDAL <u>X</u> LRL <u>X</u> CIG DEMDV SLRA
Bnip3	DIERRKEVESILKKN SDWI WDWSS	DIERRKEV <u>X</u> SIL <u>X</u> KN SDWI WDWSS
BOK-BH3	GRLAEVCAVLLRL GDE LEMIRP	GRLAEV <u>X</u> AVL <u>X</u> RL GDE LEMIRP
BAX-BH3	PQDASTKKSECLKRIG DEL DSNMEL	PQDASTKK <u>X</u> ECL <u>X</u> RIG DEL DSNMEL
BAK-BH3	PSSTMGVGRQLAI GDD INRR	PSSTMGV <u>X</u> RQL <u>X</u> I GDD INRR
BCL2L1-BH3	KQALREAG DEF ELR	<u>X</u> QAL <u>X</u> EAG DEF ELR
BCL2-BH3	LSPPVVHLALALRQAG DDF SRR	LSPPVVHL <u>X</u> LAL <u>X</u> QAG DDF SRR
BCL-XL-BH3	EVIPMAAVKQALREAG DEF ELRY	EVIPMAAV <u>X</u> QAL <u>X</u> EAG DEF ELRY
BCL-W-BH3	PADPLHQAMRAAG DEF ETRF	PADPL <u>X</u> QAM <u>X</u> AAG DEF ETRF
MCL1-BH3	ATSRKLETLRRV GDG VQRNHETA	ATSRK <u>X</u> ETL <u>X</u> RV GDG VQRNHETA
MTD-BH3	LAEVCTVLLRL GDE LEQIR	LAEV <u>X</u> TVL <u>X</u> RL GDE LEQIR
MAP-1-BH3	MTVGELSRA LGH ENGLDP	MTVGEL <u>X</u> RA LGH ENGLDP
NIX-BH3	VVEGEKEVEALKKSAD WV SDWS	VVEGEKE <u>X</u> EAL <u>X</u> KSAD WV SDWS
4ICD(ERBB4)-BH3	SMARDPQRYLVIQ GDD RMKL	SMARDP <u>X</u> RYL <u>X</u> IQ GDD RMKL

Table 2 lists human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.

TABLE 3

Name	Sequence (bold = critical residues)	Cross-linked Sequence (<u>X</u> = x-link residue)
P53 peptides		
hp53 peptide 1	LSQET FSDL WKLLPEN	LSQET FSD <u>X</u> WKLLPE <u>X</u>
hp53 peptide 2	LSQET FSDL WKLLPEN	LSQE <u>X</u> FSDL WK <u>X</u> LPEN
hp53 peptide 3	LSQET FSDL WKLLPEN	LSQ <u>X</u> T FSDLW <u>X</u> LLPEN
hp53 peptide 4	LSQET FSDL WKLLPEN	LSQET F <u>X</u> D LWKLL <u>X</u> EN
hp53 peptide 5	LSQET FSDL WKLLPEN	QSQQ T <u>F</u> <u>X</u> NLWRL <u>L</u> <u>X</u> QN

Table 3 lists human sequences which target the p53 binding site of MDM2/X and are implicated in cancers.


TABLE 4

Name	Sequence (bold = critical residues)	Cross-linked Sequence (<u>X</u> = x-link residue)
GPCR peptide ligands		
Angiotensin II	DRVYI HPF	DR <u>X</u> Y <u>X</u> HPF
Bombesin	EQRLGNQWAVG HLM	EQRLGN <u>X</u> WAVGH <u>L</u> <u>X</u>
Bradykinin	RPPGF SPFR	RPP <u>X</u> F S PFR <u>X</u>
C5a	ISHKDM QLGR	ISHKDM <u>X</u> L GR <u>X</u>
C3a	ARASH LGLAR	ARASH <u>L</u> L AR <u>X</u>
α -melanocyte stimulating hormone	SYSME HFR WGKPV	SYSM <u>X</u> H FRW <u>X</u> KPV

[0083] **Table 4** lists sequences which target human G protein-coupled receptors and are implicated in numerous human disease conditions (Tyndall *et al.* (2005), *Chem. Rev.* 105:793-826).


Peptidomimetic Macrocycles of the Invention

[0084] In some embodiments, the peptidomimetic macrocycles of the invention have the Formula (I):



wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;

B is a natural or non-natural amino acid, amino acid analog, , [-NH-L₃-CO-], [-NH-L₃-SO₂-], or [-NH-L₃-];
R₁ and R₂ are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

R_3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

L is a macrocycle-forming linker of the formula $-L_1-L_2-$;

L_1 and L_2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or $[-R_4-K-R_4-]_n$, each being optionally substituted with R_5 ;

each R_4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is O, S, SO, SO₂, CO, CO₂, or CONR₃;

each R_5 is independently halogen, alkyl, -OR₆, -N(R₆)₂, -SR₆, -SOR₆, -SO₂R₆, -CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R_6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

R_7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 , or part of a cyclic structure with a D residue;

R_8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 , or part of a cyclic structure with an E residue;

each of v and w is independently an integer from 1-1000;


each of x, y, and z is independently an integer from 0-10; u is an integer from 1-10; and

n is an integer from 1-5.

[0085] In one example, at least one of R_1 and R_2 is alkyl, unsubstituted or substituted with halo-. In another example, both R_1 and R_2 are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R_1 and R_2 is methyl. In other embodiments, R_1 and R_2 are methyl. In still other embodiments, at least one of R_1 or R_2 is an additional macrocycle linker of formula $-L_1-L_2-$. For example, a macrocycle of the invention comprises at least two crosslinkers, wherein R_1 or R_2 as shown in Formula I is a crosslinker connected to a third amino acid within the peptidomimetic macrocycle.


[0086] In some embodiments of the invention, $x+y+z$ is at least 3. In other embodiments of the invention, $x+y+z$ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula $[A]_x$, when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln-Asp-Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges.

[0087] In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α -helix and R_8 is -H, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α -disubstituted amino acid. In one example, B is an α,α -disubstituted amino acid. For instance, at least one of

A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is .


[0088] In other embodiments, the length of the macrocycle-forming linker L as measured from a first C α to a second C α is selected to stabilize a desired secondary peptide structure, such as an α -helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first C α to a second C α .

[0089] In one embodiment, the peptidomimetic macrocycle of Formula (I) is:




[0090] wherein each R_1 and R_2 is independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.


[0091] In related embodiments, the peptidomimetic macrocycle of Formula (I) is:



or




[0092] In some embodiments, the peptidomimetic macrocycle has the Formula:



wherein:

each A, A', C, C', D, and E is independently a natural or non-natural amino acid;

each B and B' is independently a natural or non-natural amino acid, amino acid analog, , $[-NH-L_3-CO-]$, $[-NH-L_3-SO_2-]$, or $[-NH-L_3-]$;

R_1 and R_2 are independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

R_3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

each L and L' is independently a macrocycle-forming linker of the formula $-L_1-L_2-$;

L_1 and L_2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or $[-R_4-K-R_4-]_n$, each being optionally substituted with R_5 ;

each R_4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is O, S, SO, SO₂, CO, CO₂, or CONR₃;

each R_5 is independently halogen, alkyl, -OR₆, -N(R₆)₂, -SR₆, -SOR₆, -SO₂R₆, -CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R_6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

R_7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 , or part of a cyclic structure with a D residue;


each R_8 and R_8' is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 , or part of a cyclic structure with an E residue;


each of v and w is independently an integer from 1-1000;

each of x , y , and z is independently an integer from 0-10; u is an integer from 1-10; and

n is an integer from 1-5.


[0093] In other embodiments, the peptidomimetic macrocycle of the invention is a compound of any of the formulas shown below:






[0094] wherein “AA” represents any natural or non-natural amino acid side chain and “” is $[D]_v$, $[E]_w$ as defined above, and n is an integer between 0 and 20, 50, 100, 200, 300, 400 or 500. In some embodiments, n is 0. In other embodiments, n is less than 50.


[0095] Exemplary embodiments of the macrocycle-forming linker L are shown below.




where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10



where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10








where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10
R = H, alkyl, other substituent




where X, Y = -CH₂-, O, S, or NH
m, n, o = 0-10

[0096] Exemplary embodiments of peptidomimetic macrocycles of the invention are shown below:




[0097] Other embodiments of peptidomimetic macrocycles of the invention include analogs of the macrocycles shown above.

[0098] In some embodiments, the peptidomimetic macrocycles of the invention have the Formula (II):



wherein:


each A, C, D, and E is independently a natural or non-natural amino acid;

B is a natural or non-natural amino acid, amino acid analog, , [-NH-L₃-CO-], [-NH-L₃-SO₂-], or [-NH-L₃-];

R₁ and R₂ are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

R₃ is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅;

L is a macrocycle-forming linker of the formula



L₁, L₂ and L₃ are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-R₄-K-R₄-]_n, each being optionally substituted with R₅;

each R₄ is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is O, S, SO, SO₂, CO, CO₂, or CONR₃;

each R₅ is independently halogen, alkyl, -OR₆, -N(R₆)₂, -SR₆, -SOR₆, -SO₂R₆, -CO₂R₆, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R₆ is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

R₇ is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with a D residue;

R₈ is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R₅, or part of a cyclic structure with an E residue;

each of v and w is independently an integer from 1-1000;


each of x, y, and z is independently an integer from 0-10; u is an integer from 1-10; and

[0099] n is an integer from 1-5.

[00100] In one example, at least one of R₁ and R₂ is alkyl, unsubstituted or substituted with halo-. In another example, both R₁ and R₂ are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R₁ and R₂ is methyl. In other embodiments, R₁ and R₂ are methyl.


[00101] In some embodiments of the invention, $x+y+z$ is at least 3. In other embodiments of the invention, $x+y+z$ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula $[A]_x$, when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln–Asp–Ala as well as embodiments where the amino acids are identical, e.g. Gln–Gln–Gln. This applies for any value of x , y , or z in the indicated ranges.


[00102] In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α -helix and R_8 is $-H$, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α -disubstituted amino acid. In one example, B is an α,α -disubstituted amino acid. For instance, at least one of

A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is .


[00103] In other embodiments, the length of the macrocycle-forming linker L as measured from a first $C\alpha$ to a second $C\alpha$ is selected to stabilize a desired secondary peptide structure, such as an α -helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first $C\alpha$ to a second $C\alpha$.

[00104] Exemplary embodiments of the macrocycle-forming linker L are shown below.






[00105] In other embodiments, the invention provides peptidomimetic macrocycles of Formula (III):



Formula (III)

wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;



B is a natural or non-natural amino acid, amino acid analog, $[-NH-L_4-CO-]$, $[-NH-L_4-SO_2-]$, or $[-NH-L_4-]$;

R_1 and R_2 are independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;

R_3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R_5 ;

L_1 , L_2 , L_3 and L_4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or $[-R_4-K-R_4-]_n$, each being unsubstituted or substituted with R_5 ;

K is O, S, SO, SO_2 , CO, CO_2 , or $CONR_3$;

each R_4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each R_5 is independently halogen, alkyl, $-OR_6$, $-N(R_6)_2$, $-SR_6$, $-SOR_6$, $-SO_2R_6$, $-CO_2R_6$, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R_6 is independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

R_7 is $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R_5 , or part of a cyclic structure with a D residue;

R_8 is $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R_5 , or part of a cyclic structure with an E residue;

each of v and w is independently an integer from 1-1000;

each of x, y, and z is independently an integer from 0-10; u is an integer from 1-10; and


n is an integer from 1-5.

[00106] In one example, at least one of R_1 and R_2 is alkyl, unsubstituted or substituted with halo-. In another example, both R_1 and R_2 are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R_1 and R_2 is methyl. In other embodiments, R_1 and R_2 are methyl.

[00107] In some embodiments of the invention, $x+y+z$ is at least 3. In other embodiments of the invention, $x+y+z$ is 3, 4, 5, 6, 7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is

independently selected. For example, a sequence represented by the formula $[A]_x$, when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln–Asp–Ala as well as embodiments where the amino acids are identical, e.g. Gln–Gln–Gln. This applies for any value of x , y , or z in the indicated ranges.

[00108] In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α -helix and R_8 is –H, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α -disubstituted amino acid. In one example, B is an α,α -disubstituted amino acid. For instance, at least one of

A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is .

[00109] In other embodiments, the length of the macrocycle-forming linker $[-L_1-S-L_2-S-L_3-]$ as measured from a first $C\alpha$ to a second $C\alpha$ is selected to stabilize a desired secondary peptide structure, such as an α -helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first $C\alpha$ to a second $C\alpha$.

[00110] Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, "The Non-Protein Amino Acids" in Chemistry and Biochemistry of the Amino Acids, edited by G.C. Barrett, Chapman and Hall, 1985. In some embodiments, the thiol moieties are the side chains of the amino acid residues L-cysteine, D-cysteine, α -methyl-L cysteine, α -methyl-D-cysteine, L-homocysteine, D-homocysteine, α -methyl-L-homocysteine or α -methyl-D-homocysteine. A bis-alkylating reagent is of the general formula $X-L_2-Y$ wherein L_2 is a linker moiety and X and Y are leaving groups that are displaced by –SH moieties to form bonds with L_2 . In some embodiments, X and Y are halogens such as I, Br, or Cl.


[00111] In other embodiments, D and/or E in the compound of Formula I, II or III are further modified in order to facilitate cellular uptake. In some embodiments, lipidating or PEGylating a peptidomimetic macrocycle facilitates cellular uptake, increases bioavailability, increases blood circulation, alters pharmacokinetics, decreases immunogenicity and/or decreases the needed frequency of administration.

[00112] In other embodiments, at least one of [D] and [E] in the compound of Formula I, II or III represents a moiety comprising an additional macrocycle-forming linker such that the peptidomimetic macrocycle comprises at least two macrocycle-forming linkers. In a specific embodiment, a peptidomimetic macrocycle comprises two macrocycle-forming linkers.

[00113] In the peptidomimetic macrocycles of the invention, any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown in Tables 1-4 and also with any of the R - substituents indicated herein.


[00114] In some embodiments, the peptidomimetic macrocycle comprises at least one α -helix motif. For example, A, B and/or C in the compound of Formula I, II or III include one or more α -helices. As a general matter, α -helices include between 3 and 4 amino acid residues per turn. In some embodiments, the α -helix of the peptidomimetic macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid residues. In specific embodiments, the α -helix includes 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns. In some embodiments, the macrocycle-forming linker stabilizes an α -helix motif included within the peptidomimetic macrocycle. Thus, in some embodiments, the length of the macrocycle-forming linker L from a first $C\alpha$ to a second $C\alpha$ is selected to increase the stability of an α -helix. In some embodiments, the macrocycle-forming linker spans from 1 turn to 5 turns of the α -helix. In some embodiments, the macrocycle-forming linker spans approximately 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns of the α -helix. In some embodiments, the length of the macrocycle-forming linker is approximately 5 Å to 9 Å per turn of the α -helix, or approximately 6 Å to 8 Å per turn of the α -helix. Where the macrocycle-forming linker spans approximately 1 turn of an α -helix, the length is equal to


[00115] In other embodiments, the invention provides peptidomimetic macrocycles of Formula (IV) or (IVa):



wherein:

each A, C, D, and E is independently a natural or non-natural amino acid;



B is a natural or non-natural amino acid, amino acid analog, , $[-NH-L_3-CO-]$, $[-NH-L_3-SO_2-]$, or $[-NH-L_3-]$;

R_1 and R_2 are independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or part of a cyclic structure with an E residue;

R_3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

L is a macrocycle-forming linker of the formula $-L_1-L_2-$;

L_1 and L_2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or $[-R_4-K-R_4-]_n$, each being optionally substituted with R_5 ;

each R_4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is O, S, SO, SO_2 , CO, CO_2 , or $CONR_3$;

each R_5 is independently halogen, alkyl, $-OR_6$, $-N(R_6)_2$, $-SR_6$, $-SOR_6$, $-SO_2R_6$, $-CO_2R_6$, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R_6 is independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;

R_7 is $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

v is an integer from 1-1000;

w is an integer from 1-1000;

x is an integer from 0-10;

y is an integer from 0-10;


z is an integer from 0-10; and

n is an integer from 1-5.

[00116] In one example, at least one of R_1 and R_2 is alkyl, unsubstituted or substituted with halo-. In another example, both R_1 and R_2 are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R_1 and R_2 is methyl. In other embodiments, R_1 and R_2 are methyl.


[00117] In some embodiments of the invention, $x+y+z$ is at least 3. In other embodiments of the invention, $x+y+z$ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula $[A]_x$, when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln-Asp-Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges.

[00118] In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α -helix and R_8 is $-H$, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α -disubstituted amino acid. In one example, B is an α,α -disubstituted amino acid. For instance, at least one of


A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is .

[00119] In other embodiments, the length of the macrocycle-forming linker L as measured from a first C α to a second C α is selected to stabilize a desired secondary peptide structure, such as an α -helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first C α to a second C α .


[00120] Exemplary embodiments of the macrocycle-forming linker L are shown below.




where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10



where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10



where X, Y = -CH₂-, O, S, or NH
m, n, o, p = 0-10
R = H, alkyl, other substituent



where X, Y = -CH₂-, O, S, or NH
m, n, o = 0-10

Preparation of Peptidomimetic Macrocycles

[00121] Peptidomimetic macrocycles of the invention may be prepared by any of a variety of methods known in the art. For example, any of the residues indicated by "X" in Tables 1, 2, 3 or 4 may be substituted with a residue capable of forming a crosslinker with a second residue in the same molecule or a precursor of such a residue.

[00122] Various methods to effect formation of peptidomimetic macrocycles are known in the art. For example, the preparation of peptidomimetic macrocycles of Formula I is described in Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000); Schafmeister & Verdine, J. Am. Chem. Soc. 122:5891 (2005); Walensky et al., Science 305:1466-1470 (2004); and US Patent No. 7,192,713. The α,α -disubstituted amino acids and amino acid precursors disclosed in the cited references may be employed in synthesis of the peptidomimetic macrocycle precursor polypeptides. Following incorporation of such amino acids into precursor polypeptides, the terminal olefins are reacted with a metathesis catalyst, leading to the formation of the peptidomimetic macrocycle.



[00123] In other embodiments, the peptidomimetic macrocycles of the invention are of Formula IV or IVa. Methods for the preparation of such macrocycles are described, for example, in US Patent No. 7,202,332.

[00124] In some embodiments, the synthesis of these peptidomimetic macrocycles involves a multi-step process that features the synthesis of a peptidomimetic precursor containing an azide moiety and an alkyne moiety; followed by contacting the peptidomimetic precursor with a macrocyclization reagent to generate a triazole-linked peptidomimetic macrocycle. Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, "The Non-Protein Amino Acids" in Chemistry and Biochemistry of the Amino Acids, edited by G.C. Barrett, Chapman and Hall, 1985.

[00125] In some embodiments, an azide is linked to the α -carbon of a residue and an alkyne is attached to the α -carbon of another residue. In some embodiments, the azide moieties are azido-analogs of amino acids L-lysine, D-lysine, α -methyl-L-lysine, α -methyl-D-lysine, L-ornithine, D-ornithine, α -methyl-L-ornithine or α -methyl-D-ornithine. In other embodiments, the azide moiety is 2-amino-7-azido-2-methylheptanoic acid or 2-amino-6-azido-2-

methylhexanoic acid. In another embodiment, the alkyne moiety is L-propargylglycine. In yet other embodiments, the alkyne moiety is an amino acid selected from the group consisting of L-propargylglycine, D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, (R)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-2-methyl-5-hexynoic acid, (R)-2-amino-2-methyl-5-hexynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, (R)-2-amino-2-methyl-6-heptynoic acid, (S)-2-amino-2-methyl-7-octynoic acid, (R)-2-amino-2-methyl-7-octynoic acid, (S)-2-amino-2-methyl-8-nonynoic acid and (R)-2-amino-2-methyl-8-nonynoic acid.

[00126] In some embodiments, the invention provides a method for synthesizing a peptidomimetic macrocycle, the method comprising the steps of contacting a peptidomimetic precursor of Formula V or Formula VI:



with a macrocyclization reagent;

wherein v , w , x , y , z , A , B , C , D , E , R_1 , R_2 , R_7 , R_8 , L_1 and L_2 are as defined for Formula (II); R_{12} is $-H$ when the macrocyclization reagent is a Cu reagent and R_{12} is $-H$ or alkyl when the macrocyclization reagent is a Ru reagent; and further wherein said contacting step results in a covalent linkage being formed between the alkyne and azide moiety in Formula III or Formula IV. For example, R_{12} may be methyl when the macrocyclization reagent is a Ru reagent.

[00127] In the peptidomimetic macrocycles of the invention, at least one of R_1 and R_2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. In some embodiments, both R_1 and R_2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of A , B , C , D or E is an α,α -disubstituted amino acid. In one example, B is an α,α -disubstituted amino acid. For instance, at least one of A , B , C , D or E is 2-aminoisobutyric acid.

[00128] For example, at least one of R_1 and R_2 is alkyl, unsubstituted or substituted with halo-. In another example, both R_1 and R_2 are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R_1 and R_2 is methyl. In other embodiments, R_1 and R_2 are methyl. The macrocyclization reagent may be a Cu reagent or a Ru reagent.

[00129] In some embodiments, the peptidomimetic precursor is purified prior to the contacting step. In other embodiments, the peptidomimetic macrocycle is purified after the contacting step. In still other embodiments, the


peptidomimetic macrocycle is refolded after the contacting step. The method may be performed in solution, or, alternatively, the method may be performed on a solid support.

[00130] Also envisioned herein is performing the method of the invention in the presence of a target macromolecule that binds to the peptidomimetic precursor or peptidomimetic macrocycle under conditions that favor said binding. In some embodiments, the method is performed in the presence of a target macromolecule that binds preferentially to the peptidomimetic precursor or peptidomimetic macrocycle under conditions that favor said binding. The method may also be applied to synthesize a library of peptidomimetic macrocycles.


[00131] In some embodiments, the alkyne moiety of the peptidomimetic precursor of Formula V or Formula VI is a sidechain of an amino acid selected from the group consisting of L-propargylglycine, D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, (R)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-2-methyl-5-hexynoic acid, (R)-2-amino-2-methyl-5-hexynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, (R)-2-amino-2-methyl-6-heptynoic acid, (S)-2-amino-2-methyl-7-octynoic acid, (R)-2-amino-2-methyl-7-octynoic acid, (S)-2-amino-2-methyl-8-nonynoic acid, and (R)-2-amino-2-methyl-8-nonynoic acid. In other embodiments, the azide moiety of the peptidomimetic precursor of Formula V or Formula VI is a sidechain of an amino acid selected from the group consisting of ϵ -azido-L-lysine, ϵ -azido-D-lysine, ϵ -azido- α -methyl-L-lysine, ϵ -azido- α -methyl-D-lysine, δ -azido- α -methyl-L-ornithine, and δ -azido- α -methyl-D-ornithine.

[00132] In some embodiments, $x+y+z$ is 3, and A, B and C are independently natural or non-natural amino acids. In other embodiments, $x+y+z$ is 6, and A, B and C are independently natural or non-natural amino acids.

[00133] In some embodiments of peptidomimetic macrocycles of the invention, $[D]_v$ and/or $[E]_w$ comprise additional peptidomimetic macrocycles or macrocyclic structures. For example, $[D]_v$ may have the formula:



wherein each A, C, D', and E' is independently a natural or non-natural amino acid;



B is a natural or non-natural amino acid, amino acid analog, $[-NH-L_3-CO-]$, $[-NH-L_3-SO_2-]$, or $[-NH-L_3-]$;

R_1 and R_2 are independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or part of a cyclic structure with an E residue;

R_3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

L_1 and L_2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or $[-R_4-K-R_4-]_n$, each being optionally substituted with R_5 ;

each R_4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;

each K is O, S, SO, SO_2 , CO, CO_2 , or $CONR_3$;

each R_5 is independently halogen, alkyl, $-OR_6$, $-N(R_6)_2$, $-SR_6$, $-SOR_6$, $-SO_2R_6$, $-CO_2R_6$, a fluorescent moiety, a radioisotope or a therapeutic agent;

each R_6 is independently $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;


R_7 is $-H$, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R_5 ;

v is an integer from 1-1000;

w is an integer from 1-1000; and

x is an integer from 0-10.

[00134] In another embodiment, $[E]_w$ has the formula:



, wherein the substituents are as defined in the

preceding paragraph.

[00135] In some embodiments, the contacting step is performed in a solvent selected from the group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof. For example, the solvent may be chosen from the group consisting of H_2O , THF, THF/ H_2O , $tBuOH/H_2O$, DMF, DIPEA, CH_3CN or CH_2Cl_2 , $ClCH_2CH_2Cl$ or a mixture thereof. The solvent may be a solvent which favors helix formation.

[00136] Alternative but equivalent protecting groups, leaving groups or reagents are substituted, and certain of the synthetic steps are performed in alternative sequences or orders to produce the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein include, for example, those such as described in Larock, Comprehensive Organic Transformations, VCH Publishers (1989); Greene and Wuts, Protective Groups in Organic Synthesis, 2d. Ed. , John Wiley and Sons (1991); Fieser and Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

[00137] The peptidomimetic macrocycles of the invention are made, for example, by chemical synthesis methods, such as described in Fields *et al.*, Chapter 3 in Synthetic Peptides: A User's Guide, ed. Grant, W. H. Freeman & Co., New York, N. Y., 1992, p. 77. Hence, for example, peptides are synthesized using the automated Merrifield techniques of solid phase synthesis with the amine protected by either tBoc or Fmoc chemistry using side chain protected amino acids on, for example, an automated peptide synthesizer (*e.g.*, Applied Biosystems (Foster City, CA), Model 430A, 431, or 433).


[00138] One manner of producing the peptidomimetic precursors and peptidomimetic macrocycles described herein uses solid phase peptide synthesis (SPPS). The C-terminal amino acid is attached to a cross-linked polystyrene resin *via* an acid labile bond with a linker molecule. This resin is insoluble in the solvents used for synthesis, making it relatively simple and fast to wash away excess reagents and by-products. The N-terminus is protected with the Fmoc group, which

is stable in acid, but removable by base. Side chain functional groups are protected as necessary with base stable, acid labile groups.


[00139] Longer peptidomimetic precursors are produced, for example, by conjoining individual synthetic peptides using native chemical ligation. Alternatively, the longer synthetic peptides are biosynthesized by well known recombinant DNA and protein expression techniques. Such techniques are provided in well-known standard manuals with detailed protocols. To construct a gene encoding a peptidomimetic precursor of this invention, the amino acid sequence is reverse translated to obtain a nucleic acid sequence encoding the amino acid sequence, preferably with codons that are optimum for the organism in which the gene is to be expressed. Next, a synthetic gene is made, typically by synthesizing oligonucleotides which encode the peptide and any regulatory elements, if necessary. The synthetic gene is inserted in a suitable cloning vector and transfected into a host cell. The peptide is then expressed under suitable conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods.

[00140] The peptidomimetic precursors are made, for example, in a high-throughput, combinatorial fashion using, for example, a high-throughput polychannel combinatorial synthesizer (*e.g.*, Thuramed TETRAS multichannel peptide synthesizer from CreoSalus, Louisville, KY or Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, KY).

[00141] The following synthetic schemes are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein. To simplify the drawings, the illustrative schemes depict azido amino acid analogs ϵ -azido- α -methyl-L-lysine and ϵ -azido- α -methyl-D-lysine, and alkyne amino acid analogs L-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, and (S)-2-amino-2-methyl-6-heptynoic acid. Thus, in the following synthetic schemes, each R_1 , R_2 , R_7 and R_8 is -H; each L_1 is $-(CH_2)_4-$; and each L_2 is $-(CH_2)-$. However, as noted throughout the detailed description above, many other amino acid analogs can be employed in which R_1 , R_2 , R_7 , R_8 , L_1 and L_2 can be independently selected from the various structures disclosed herein.

[00142] Synthetic Scheme 1:


[00143] Synthetic Scheme 1 describes the preparation of several compounds of the invention. Ni(II) complexes of Schiff bases derived from the chiral auxiliary (S)-2-[N-(N'-benzylprolyl)amino]benzophenone (BPB) and amino acids such as glycine or alanine are prepared as described in Belokon *et al.* (1998), *Tetrahedron Asymm.* 9:4249-4252. The resulting complexes are subsequently reacted with alkylating reagents comprising an azido or alkynyl moiety to yield enantiomerically enriched compounds of the invention. If desired, the resulting compounds can be protected for use in peptide synthesis. In some embodiments of Synthetic Scheme 1, X is iodine.

[00144] Synthetic Scheme 2:

[00145] In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 2, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N- α -Fmoc-L-propargylglycine and the N- α -Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl- ϵ -azido-L-lysine, and N-methyl- ϵ -azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Cu(I) in organic or aqueous solutions (Rostovtsev *et al.* (2002), *Angew. Chem. Int.*

Ed. 41:2596-2599; Tornøe *et al.* (2002), *J. Org. Chem.* 67:3057-3064; Deiters *et al.* (2003), *J. Am. Chem. Soc.* 125:11782-11783; Punna *et al.* (2005), *Angew. Chem. Int. Ed.* 44:2215-2220). In one embodiment, the triazole forming reaction is performed under conditions that favor α -helix formation. In one embodiment, the macrocyclization step is performed in a solvent chosen from the group consisting of H₂O, THF, CH₃CN, DMF, DIPEA, tBuOH or a mixture thereof. In another embodiment, the macrocyclization step is performed in DMF. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent.


[00146] Synthetic Scheme 3:



[00147] In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 3, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide


synthesis (SPPS) using the commercially available amino acid N- α -Fmoc-L-propargylglycine and the N- α -Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl- ϵ -azido-L-lysine, and N-methyl- ϵ -azido-D-lysine. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Cu(I) reagent on the resin as a crude mixture (Rostovtsev *et al.* (2002), *Angew. Chem. Int. Ed.* 41:2596-2599; Tornøe *et al.* (2002), *J. Org. Chem.* 67:3057-3064; Deiters *et al.* (2003), *J. Am. Chem. Soc.* 125:11782-11783; Punna *et al.* (2005), *Angew. Chem. Int. Ed.* 44:2215-2220). The resultant triazole-containing peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH₂Cl₂, ClCH₂CH₂Cl, DMF, THF, NMP, DIPEA, 2,6-lutidine, pyridine, DMSO, H₂O or a mixture thereof. In some embodiments, a solution of a reducing agent such as sodium ascorbate may be used. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent.

[00148] Synthetic Scheme 4:



[00149] In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 4, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N- α -Fmoc-L-propargylglycine and the N- α -Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl- ϵ -azido-L-lysine, and N-methyl- ϵ -azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Ru(II) reagents, for example Cp* $\text{RuCl}(\text{PPh}_3)_2$ or [Cp* RuCl] $_4$ (Rasmussen *et al.* (2007), *Org. Lett.* 9:5337-5339; Zhang *et al.* (2005), *J. Am. Chem. Soc.* 127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of DMF, CH $_3$ CN, benzene, toluene and THF.


[00150] Synthetic Scheme 5:



[00151] In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 5, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide synthesis (SPPS) using the commercially available amino acid N- α -Fmoc-L-propargylglycine and the N- α -Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl- ϵ -azido-L-lysine, N-methyl- ϵ -azido-D-lysine, 2-amino-7-azido-2-methylheptanoic acid and 2-amino-6-azido-2-methylhexanoic acid. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Ru(II) reagent on the resin as a crude mixture. For example, the reagent can be Cp*RuCl(PPh₃)₂ or [Cp*RuCl]₄ (Rasmussen *et al.* (2007), *Org. Lett.* 9:5337-5339; Zhang *et al.* (2005), *J. Am. Chem. Soc.* 127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH₂Cl₂, ClCH₂CH₂Cl, CH₃CN, DMF, benzene, toluene and THF.

[00152] Several exemplary peptidomimetic macrocycles are shown in Table 5. "Nle" represents norleucine and replaces a methionine residue. It is envisioned that similar linkers are used to synthesize peptidomimetic macrocycles based on the polypeptide sequences disclosed in Table 1 through Table 4.

TABLE 5






Table 5 shows exemplary peptidomimetic macrocycles of the invention. “Nle” represents norleucine.

[00153] The present invention contemplates the use of non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles described herein. Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable triazole containing peptidomimetic macrocycles can be used in the present invention. For example, L-propargylglycine is contemplated as a useful amino acid in the present invention. However, other alkyne-containing amino acids that contain a different amino acid side chain are also useful in the invention. For example, L-propargylglycine contains one methylene unit between the α -carbon of the amino acid and the alkyne of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α -carbon and the alkyne. Also, the azido-analogs of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, and alpha-methyl-D-lysine are contemplated as useful amino acids in the present invention. However, other terminal azide amino acids that contain a different amino acid side chain are also useful in the invention. For example, the azido-analog of L-lysine contains four methylene units between the α -carbon of the amino acid and the terminal azide of the amino acid side chain. The invention also contemplates the use of amino acids with fewer than or greater than four methylene units between the α -carbon and the terminal azide. Table 6 shows some amino acids useful in the preparation of peptidomimetic macrocycles of the invention.

TABLE 6

N-α-Fmoc-L-propargyl glycine	N-α-Fmoc-D-propargyl glycine		
N-α-Fmoc-(S)-2-amino-2-methyl-4-pentynoic acid	N-α-Fmoc-(R)-2-amino-2-methyl-4-pentynoic acid	(R)-2-(Fmoc-amino)-8-azido-octanoic acid	(R)-2-(Fmoc-amino)-7-azidoheptanoic acid
N-α-Fmoc-(S)-2-amino-2-methyl-5-hexynoic acid	N-α-Fmoc-(R)-2-amino-2-methyl-5-hexynoic acid	(R)-2-(Fmoc-amino)-8-azido-2-methyloctanoic acid	(R)-2-(Fmoc-amino)-7-azido-2-methylheptanoic acid
N-α-Fmoc-(S)-2-amino-2-methyl-6-heptynoic acid	N-α-Fmoc-(R)-2-amino-2-methyl-6-heptynoic acid	N-α-Fmoc-δ-azido-L-ornithine	N-α-Fmoc-ε-azido-L-lysine
N-α-Fmoc-(S)-2-amino-2-methyl-7-octynoic acid	N-α-Fmoc-(R)-2-amino-2-methyl-7-octynoic acid	N-α-Fmoc-ε-azido-α-methyl-L-ornithine	N-α-Fmoc-ε-azido-α-methyl-L-lysine
N-α-Fmoc-(S)-2-amino-2-methyl-8-nonynoic acid	N-α-Fmoc-(R)-2-amino-2-methyl-8-nonynoic acid		


Table 6 shows exemplary amino acids useful in the preparation of peptidomimetic macrocycles of the invention.

[00154] In some embodiments the amino acids and amino acid analogs are of the D-configuration. In other embodiments they are of the L-configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D-configuration while some of the amino acids and amino acid analogs are of the L-configuration. In some embodiments the amino acid analogs are α,α -disubstituted, such as α -methyl-L-propargylglycine, α -methyl-D-propargylglycine, ϵ -azido- α -methyl-L-lysine, and ϵ -azido- α -methyl-D-lysine. In some embodiments the amino acid analogs are N-alkylated, *e.g.*, N-methyl-L-propargylglycine, N-methyl-D-propargylglycine, N-methyl- ϵ -azido-L-lysine, and N-methyl- ϵ -azido-D-lysine.

[00155] In some embodiments, the -NH moiety of the amino acid is protected using a protecting group, including without limitation -Fmoc and -Boc. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle.

[00156] In other embodiments, peptidomimetic macrocycles of Formula III are synthesized. The following synthetic schemes describe the preparation of such compounds. To simplify the drawings, the illustrative schemes depict amino acid analogs derived from L-or D-cysteine, in which L_1 and L_3 are both $-(CH_2)-$. However, as noted throughout the detailed description above, many other amino acid analogs can be employed in which L_1 and L_3 can be independently selected from the various structures disclosed herein. The symbols “[AA]_m”, “[AA]_n”, “[AA]_o” represent a sequence of amide bond-linked moieties such as natural or unnatural amino acids. As described previously, each occurrence of “AA” is independent of any other occurrence of “AA”, and a formula such as “[AA]_m” encompasses, for example, sequences of non-identical amino acids as well as sequences of identical amino acids.


Synthetic Scheme 6:



[00157] In Scheme 6, the peptidomimetic precursor contains two -SH moieties and is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N- α -Fmoc amino acids such as N- α -Fmoc-S-trityl-L-cysteine or N- α -Fmoc-S-trityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach *et al.* (1996), *Angew. Chem. Int. Ed. Engl.* 35:2708-2748, and references therein) and then converted to the appropriately protected N- α -Fmoc-S-trityl monomers by known methods ("Bioorganic Chemistry: Peptides and Proteins", Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The precursor peptidomimetic is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA). The precursor peptidomimetic is reacted as a crude mixture or is purified prior to

reaction with X-L₂-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH₃ (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH₃/MeOH, or NH₃/DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the solvent used for the alkylation reaction is DMF or dichloroethane.


Synthetic Scheme 7:



[00158] In Scheme 7, the precursor peptidomimetic contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The precursor peptidomimetic is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N- α -Fmoc amino acids such as N- α -Fmoc-S-*p*-methoxytrityl-L-cysteine or N- α -Fmoc-S-*p*-methoxytrityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach *et al.* (1996), *Angew. Chem. Int. Ed. Engl.* 35:2708-2748, and references therein) and then converted to the appropriately protected N- α -Fmoc-S-*p*-methoxytrityl monomers by known methods (*Bioorganic Chemistry: Peptides and Proteins*, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The Mmt protecting groups of the peptidomimetic precursor are then selectively cleaved by standard conditions (*e.g.*, mild acid such as 1% TFA in DCM).

The precursor peptidomimetic is then reacted on the resin with X-L₂-Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH₃ (Mosberg *et al.* (1985), *J. Am. Chem. Soc.* 107:2986-2987; Szewczuk *et al.* (1992), *Int. J. Peptide Protein Res.* 40 :233-242), NH₃/MeOH or NH₃/DMF (Or *et al.* (1991), *J. Org. Chem.* 56:3146-3149). In other embodiments, the alkylation reaction is performed in DMF or dichloroethane. The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA).


Synthetic Scheme 8:



[00159] In Scheme 8, the peptidomimetic precursor contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The peptidomimetic precursor is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N- α -Fmoc amino acids such as N- α -Fmoc-S-*p*-methoxytrityl-L-cysteine, N- α -Fmoc-S-*p*-methoxytrityl-D-cysteine, N- α -Fmoc-S-S-t-butyl-L-cysteine, and N- α -Fmoc-S-S-t-butyl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach *et al.* (1996), *Angew. Chem. Int. Ed. Engl.* 35:2708-2748, and references therein) and then converted to the appropriately protected N- α -Fmoc-S-*p*-methoxytrityl or N- α -Fmoc-S-S-t-butyl monomers by known methods (*Bioorganic Chemistry: Peptides and Proteins*, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The S-S-tButyl protecting group of the peptidomimetic precursor is selectively cleaved by known conditions (*e.g.*, 20% 2-mercaptoethanol in DMF, reference: Galande *et al.* (2005), *J. Comb. Chem.* 7:174-177). The precursor peptidomimetic is then reacted on the resin with a molar excess of X-L₂-Y in

an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. The Mmt protecting group of the peptidomimetic precursor is then selectively cleaved by standard conditions (*e.g.*, mild acid such as 1% TFA in DCM). The peptidomimetic precursor is then cyclized on the resin by treatment with a hindered base in organic solutions. In some embodiments, the alkylation reaction is performed in organic solutions such as NH_3/MeOH or NH_3/DMF (Or *et al.* (1991), *J. Org. Chem.* 56:3146-3149). The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (*e.g.*, strong acid such as 95% TFA).

Synthetic Scheme 9:



[00160] In Scheme 9, the peptidomimetic precursor contains two L-cysteine moieties. The peptidomimetic precursor is synthesized by known biological expression systems in living cells or by known *in vitro*, cell-free, expression methods. The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (*i.e.* 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH_3 (Mosberg *et al.* (1985), *J. Am.Chem. Soc.* 107:2986-2987; Szewczuk *et al.* (1992), *Int. J. Peptide Protein Res.* 40 :233-242), NH_3/MeOH , or NH_3/DMF (Or *et al.* (1991), *J. Org. Chem.* 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel *et al.* (2005), *Chem. Commun.* (20):2552-2554). In other embodiments, the alkylation is performed in DMF or dichloroethane. In another embodiment, the alkylation is performed in non-denaturing aqueous solutions, and in yet another embodiment the alkylation is performed under conditions that favor α -helical structure formation. In yet another embodiment, the alkylation is performed under conditions that favor the binding of the precursor peptidomimetic to another protein, so as to induce the formation of the bound α -helical conformation during the alkylation.


[00161] Various embodiments for X and Y are envisioned which are suitable for reacting with thiol groups. In general, each X or Y is independently selected from the general category shown in Table 5. For example, X and Y are halides such as $-\text{Cl}$, $-\text{Br}$ or $-\text{I}$. Any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown in Tables 1-4 and also with any of the R- substituents indicated herein.

TABLE 7: Examples of Reactive Groups Capable of Reacting with Thiol Groups and Resulting Linkages

X or Y	Resulting Covalent Linkage
acrylamide	Thioether
halide (<i>e.g.</i> alkyl or aryl halide)	Thioether
sulfonate	Thioether
aziridine	Thioether
epoxide	Thioether
haloacetamide	Thioether
maleimide	Thioether
sulfonate ester	Thioether

[00162] Table 8 shows exemplary macrocycles of the invention. “N_L” represents norleucine and replaces a methionine residue. It is envisioned that similar linkers are used to synthesize peptidomimetic macrocycles based on the polypeptide sequences disclosed in Table 1 through Table 4.

TABLE 8: Examples of Peptidomimetic Macrocycles of the Invention



For the examples shown in this table, “N_L” represents norleucine.

[00163] The present invention contemplates the use of both naturally-occurring and non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles of Formula (III). Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable bis-sulfhydryl containing peptidomimetic macrocycles can be used in the present invention. For example, cysteine is contemplated as a useful

amino acid in the present invention. However, sulfur containing amino acids other than cysteine that contain a different amino acid side chain are also useful. For example, cysteine contains one methylene unit between the α -carbon of the amino acid and the terminal -SH of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α -carbon and the terminal -SH. Non-limiting examples include α -methyl-L-homocysteine and α -methyl-D-homocysteine. In some embodiments the amino acids and amino acid analogs are of the D- configuration. In other embodiments they are of the L- configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D- configuration while some of the amino acids and amino acid analogs are of the L- configuration. In some embodiments the amino acid analogs are α,α -disubstituted, such as α -methyl-L-cysteine and α -methyl-D-cysteine.


[00164] The invention includes macrocycles in which macrocycle-forming linkers are used to link two or more -SH moieties in the peptidomimetic precursors to form the peptidomimetic macrocycles of the invention. As described above, the macrocycle-forming linkers impart conformational rigidity, increased metabolic stability and/or increased cell penetrability. Furthermore, in some embodiments, the macrocycle-forming linkages stabilize the α -helical secondary structure of the peptidomimetic macrocycles. The macrocycle-forming linkers are of the formula $X-L_2-Y$, wherein both X and Y are the same or different moieties, as defined above. Both X and Y have the chemical characteristics that allow one macrocycle-forming linker $-L_2-$ to bis alkylate the bis-sulfhydryl containing peptidomimetic precursor. As defined above, the linker $-L_2-$ includes alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene, or $-R_4-K-R_4-$, all of which can be optionally substituted with an R_5 group, as defined above. Furthermore, one to three carbon atoms within the macrocycle-forming linkers $-L_2-$, other than the carbons attached to the -SH of the sulfhydryl containing amino acid, are optionally substituted with a heteroatom such as N, S or O.

[00165] The L_2 component of the macrocycle-forming linker $X-L_2-Y$ may be varied in length depending on, among other things, the distance between the positions of the two amino acid analogs used to form the peptidomimetic macrocycle. Furthermore, as the lengths of L_1 and/or L_3 components of the macrocycle-forming linker are varied, the length of L_2 can also be varied in order to create a linker of appropriate overall length for forming a stable peptidomimetic macrocycle. For example, if the amino acid analogs used are varied by adding an additional methylene unit to each of L_1 and L_3 , the length of L_2 are decreased in length by the equivalent of approximately two methylene units to compensate for the increased lengths of L_1 and L_3 .

[00166] In some embodiments, L_2 is an alkylene group of the formula $-(CH_2)_n-$, where n is an integer between about 1 and about 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In other embodiments, L_2 is an alkenylene group. In still other embodiments, L_2 is an aryl group.

[00167] Table 9 shows additional embodiments of X-L₂-Y groups.

TABLE 9. Exemplary X-L₂-Y groups of the invention.



Each X and Y in this table, is, for example, independently Cl-, Br- or I-.

[00168] Additional methods of forming peptidomimetic macrocycles which are envisioned as suitable to perform the present invention include those disclosed by Mustapa, M. Firouz Mohd et al., J. Org. Chem (2003), 68, pp. 8193-8198; Yang, Bin et al. Bioorg Med. Chem. Lett. (2004), 14, pp. 1403-1406; U.S. Patent No. 5,364,851; U.S. Patent No. 5,446,128; U.S. Patent No. 5,824,483; U.S. Patent No. 6,713,280; U.S. Patent No. 7,202,332; and WO 2008/121767, all of which are incorporated by reference. In such embodiments, aminoacid precursors are used containing an additional substituent R- at the alpha position. Such aminoacids are incorporated into the macrocycle precursor at the desired positions, which may be at the positions where the crosslinker is substituted or, alternatively, elsewhere in the sequence of the macrocycle precursor. Cyclization of the precursor is then effected according to the indicated method.

Assays

[00169] The properties of the peptidomimetic macrocycles of the invention are assayed, for example, by using the methods described below. In some embodiments, a peptidomimetic macrocycle of the invention has improved biological properties relative to a corresponding polypeptide lacking the substituents described herein.

Assay to Determine α -helicity.

[00170] In solution, the secondary structure of polypeptides with α -helical domains will reach a dynamic equilibrium between random coil structures and α -helical structures, often expressed as a “percent helicity”. Thus, for example, unmodified pro-apoptotic BH3 domains are predominantly random coils in solution, with α -helical content usually under 25%. Peptidomimetic macrocycles with optimized linkers, on the other hand, possess, for example, an α -helicity that is at least two-fold greater than that of a corresponding macrocycle lacking the R- substituent. In some embodiments, macrocycles of the invention will possess an α -helicity of greater than 50%. To assay the helicity of peptidomimetic macrocycles of the invention, such as BH3 domain-based macrocycles, the compounds are dissolved in an aqueous solution (e.g. 50 mM potassium phosphate solution at pH 7, or distilled H₂O, to concentrations of 25-50 μ M). Circular dichroism (CD) spectra are obtained on a spectropolarimeter (e.g., Jasco J-710) using standard measurement parameters (e.g. temperature, 20°C; wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm). The α -helical content of each peptide is calculated by dividing the mean residue ellipticity (e.g. $[\Phi]_{222\text{obs}}$) by the reported value for a model helical decapeptide (Yang *et al.* (1986), *Methods Enzymol.* 130:208)).

Assay to Determine Melting Temperature (T_m).

[00171] A peptidomimetic macrocycle of the invention comprising a secondary structure such as an α -helix exhibits, for example, a higher melting temperature than a corresponding macrocycle lacking the R- substituent. Typically peptidomimetic macrocycles of the invention exhibit T_m of > 60°C representing a highly stable structure in aqueous solutions. To assay the effect of macrocycle formation on melting temperature, peptidomimetic macrocycles or unmodified peptides are dissolved in distilled H₂O (e.g. at a final concentration of 50 μ M) and the T_m is determined by measuring the change in ellipticity over a temperature range (e.g. 4 to 95 °C) on a spectropolarimeter (e.g., Jasco J-710) using standard parameters (e.g. wavelength 222nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature increase rate: 1°C/min; path length, 0.1 cm).

Protease Resistance Assay.

[00172] The amide bond of the peptide backbone is susceptible to hydrolysis by proteases, thereby rendering peptidic compounds vulnerable to rapid degradation *in vivo*. Peptide helix formation, however, typically buries the amide backbone and therefore may shield it from proteolytic cleavage. The peptidomimetic macrocycles of the present invention may be subjected to *in vitro* pepsin and trypsin proteolysis to assess for any change in degradation rate compared to a corresponding uncrosslinked) polypeptide. For example, the peptidomimetic macrocycle and a corresponding (unsubstituted) polypeptide are incubated with peptidases, pepsin or trypsin immobilized on silica gel and the reactions quenched at various time points by addition of 2% trifluoroacetic acid in acetonitrile / 1,1,1,3,3,3-hexafluoro-2-propanol. Subsequent HPLC injection is made for mass spectrometry-based quantification of the residual substrate in the multiple-reaction monitoring mode (MRM) of chromatographic peak detection. Briefly, the peptidomimetic macrocycle and peptidomimetic precursor (5 μ M) are incubated with pepsin or trypsin silica gel (Princeton Separations) (S/E ~50) for 0, 10, 20, 30, and 60 minutes. Reactions are quenched by addition of 2%

trifluoroacetic acid in acetonitrile / 1,1,1,3,3,3-hexafluoro-2-propanol, and remaining substrate in the isolated supernatant is quantified by MRM peak detection. The proteolytic reaction displays first order kinetics and the rate constant, k , is determined from a plot of $\ln[S]$ versus time ($k = -1 \times \text{slope}$). The reaction half-life is calculated using the formula $T_{1/2} = \ln 2/k$.

Ex Vivo Stability Assay.

[00173] Peptidomimetic macrocycles with optimized linkers possess, for example, an *ex vivo* half-life that is at least two-fold greater than that of a corresponding macrocycle lacking the R- substituent, and possess an *ex vivo* half-life of 12 hours or more. For *ex vivo* serum stability studies, a variety of assays may be used. For example, a peptidomimetic macrocycle and a corresponding macrocycle lacking the R- substituent (2 mcg) are incubated with fresh mouse, rat and/or human serum (2 mL) at 37°C for 0, 1, 2, 4, 8, and 24 hours. Samples of differing macrocycle concentration may be prepared by serial dilution with serum. To determine the level of intact compound, the following procedure may be used: The samples are extracted by transferring 100 μ L of sera to 2 mL centrifuge tubes followed by the addition of 10 μ L of 50 % formic acid and 500 μ L acetonitrile and centrifugation at 14,000 RPM for 10 min at $4 \pm 2^\circ\text{C}$. The supernatants are then transferred to fresh 2 mL tubes and evaporated on Turbovap under $\text{N}_2 < 10$ psi, 37°C. The samples are reconstituted in 100 μ L of 50:50 acetonitrile:water and submitted to LC-MS/MS analysis. Equivalent or similar procedures for testing *ex vivo* stability are known and may be used to determine stability of macrocycles in serum.

In vitro Binding Assays.

[00174] To assess the binding and affinity of peptidomimetic macrocycles and peptidomimetic precursors to acceptor proteins, a fluorescence polarization assay (FPA) may be used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (*e.g.*, FITC) attached to molecules with high apparent molecular weights (*e.g.* FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (*e.g.* FITC- labeled peptides that are free in solution).

[00175] For example, fluoresceinated peptidomimetic macrocycles (25 nM) are incubated with the acceptor protein (25-1000 nM) in binding buffer (140 mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (*e.g.* Perkin-Elmer LS50B). K_d values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, CA). A peptidomimetic macrocycle of the invention shows, in some instances, similar or lower K_d than a corresponding macrocycle lacking the R- substituent.

[00176] Acceptor proteins for BH3-peptides such as BCL-2, BCL-X_L, BAX or MCL1 may, for example, be used in this assay. Acceptor proteins for p53 peptides such as MDM2 or MDMX may also be used in this assay.

In vitro Displacement Assays To Characterize Antagonists of Peptide-Protein Interactions.

[00177] To assess the binding and affinity of compounds that antagonize the interaction between a peptide (*e.g.* a BH3 peptide or a p53 peptide) and an acceptor protein, a fluorescence polarization assay (FPA) utilizing a fluoresceinated peptidomimetic macrocycle derived from a peptidomimetic precursor sequence is used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (*e.g.*, FITC) attached to molecules with high apparent molecular weights (*e.g.* FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of

rotation as compared to fluorescent tracers attached to smaller molecules (*e.g.* FITC-labeled peptides that are free in solution). A compound that antagonizes the interaction between the fluoresceinated peptidomimetic macrocycle and an acceptor protein will be detected in a competitive binding FPA experiment.

[00178] For example, putative antagonist compounds (1 nM to 1 mM) and a fluoresceinated peptidomimetic macrocycle (25 nM) are incubated with the acceptor protein (50 nM) in binding buffer (140mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Antagonist binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (*e.g.* Perkin-Elmer LS50B). K_d values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, CA).

[00179] Any class of molecule, such as small organic molecules, peptides, oligonucleotides or proteins can be examined as putative antagonists in this assay. Acceptor proteins for BH3-peptides such as BCL2, BCL-XL, BAX or MCL1 can be used in this assay. Additional methods to perform such assays are described in the Example section below.

Binding Assays in Cell Lysates or Intact Cells.

[00180] It is possible to measure binding of peptides or peptidomimetic macrocycles to their natural acceptors in cell lysates or intact cells by immunoprecipitation and pull-down experiments. For example, intact cells are incubated with fluoresceinated (FITC-labeled) or biotinylated compounds for 4 hrs in the absence of serum, followed by serum replacement and further incubation that ranges from 4-18 hrs. Alternatively, cells can be incubated for the duration of the experiment in Opti-MEM (Invitrogen). Cells are then pelleted and incubated in lysis buffer (50mM Tris [pH 7.6], 150 mM NaCl, 1% CHAPS and protease inhibitor cocktail) for 10 minutes at 4°C. 1% NP-40 or Triton X-100 may be used instead of CHAPS. Extracts are centrifuged at 14,000 rpm for 15 minutes and supernatants collected and incubated with 10 μ l goat anti-FITC antibody or streptavidin-coated beads for 2 hrs, rotating at 4°C followed by further 2 hrs incubation at 4°C with protein A/G Sepharose (50 μ l of 50% bead slurry).). No secondary step is necessary if using streptavidin beads to pull down biotinylated compounds. Alternatively FITC-labeled or biotinylated compounds are incubated with cell lysates, prepared as described above, for 2 hrs, rotating at 4°C followed by incubation with 10 μ l goat anti-FITC antibody or streptavidin-coated beads for 2 hrs, rotating at 4°C followed by further 2 hrs incubation at 4°C with protein A/G Sepharose (50 μ l of 50% bead slurry), no secondary step is necessary if using streptavidin beads to pull down biotinylated compounds. After quick centrifugation, the pellets may be washed in lysis buffer containing increasing salt concentration (*e.g.*, 150, 300, 500 mM of NaCl). The beads may be then re-equilibrated at 150 mM NaCl before addition of SDS-containing sample buffer and boiling. The beads and cell lysates may be electrophoresed using 4%-12% gradient Bis-Tris gels followed by transfer into Immobilon-P membranes. After blocking, blots may be incubated with an antibody that detects FITC or biotin, respectively and also with one or more antibodies that detect proteins that bind to the peptidomimetic macrocycle, including BCL2, MCL1, BCL-XL, A1, BAX, and BAK. The lysate blots are also probed with anti-Hsc-70 for loading control. Alternatively, after electrophoresis the gel may be silver stained to detect proteins that come down specifically with FITC-labeled or biotinylated compounds.

Cellular Penetrability Assays.

[00181] A peptidomimetic macrocycle is, for example, more cell permeable compared to a corresponding macrocycle lacking the R- substituent. In some embodiments, the peptidomimetic macrocycles are more cell permeable than a corresponding macrocycle lacking the R- substituents. Peptidomimetic macrocycles with optimized linkers possess, for example, cell penetrability that is at least two-fold greater than a corresponding macrocycle lacking the R- substituent, and often 20% or more of the applied peptidomimetic macrocycle will be observed to have penetrated the cell after 4

hours. To measure the cell penetrability of peptidomimetic macrocycles and corresponding macrocycle lacking the R-substituents, intact cells are incubated with fluoresceinated peptidomimetic macrocycles or corresponding uncrosslinked polypeptides (10 μ M) for 4 hrs in serum free media at 37°C, washed twice with media and incubated with trypsin (0.25%) for 10 min at 37°C. The cells are washed again and resuspended in PBS. Cellular fluorescence is analyzed, for example, by using either a FACSCalibur flow cytometer or Cellomics' KineticScan® HCS Reader. Additional methods of quantitating cellular penetration may be used. A particular method is described in more detail in the Examples provided.

Cellular Efficacy Assays.

[00182] The efficacy of certain peptidomimetic macrocycles is determined, for example, in cell-based killing assays using a variety of tumorigenic and non-tumorigenic cell lines and primary cells derived from human or mouse cell populations. Cell viability is monitored, for example, over 24-96 hrs of incubation with peptidomimetic macrocycles (0.5 to 50 μ M) to identify those that kill at $EC_{50} < 10 \mu$ M. In this context, EC_{50} refers to the half maximal effective concentration, which is the concentration of peptidomimetic macrocycle at which 50% the population is viable. Several standard assays that measure cell viability are commercially available and are optionally used to assess the efficacy of the peptidomimetic macrocycles. In addition, assays that measure Annexin V and caspase activation are optionally used to assess whether the peptidomimetic macrocycles kill cells by activating the apoptotic machinery. For example, the Cell Titer-glo assay is used which determines cell viability as a function of intracellular ATP concentration.

In Vivo Stability Assay.

[00183] To investigate the *in vivo* stability of the peptidomimetic macrocycles, the compounds are, for example, administered to mice and/or rats by IV, IP, SC, PO or inhalation routes at concentrations ranging from 0.1 to 50 mg/kg and blood specimens withdrawn at 0', 5', 15', 30', 1 hr, 4 hrs, 8 hrs, 12 hrs, 24 hrs and 48 hrs post-injection. Levels of intact compound in 25 μ L of fresh serum are then measured by LC-MS/MS as described herein.

In vivo Efficacy in Animal Models.

[00184] To determine the anti-oncogenic activity of peptidomimetic macrocycles of the invention *in vivo*, the compounds are, for example, given alone (IP, IV, SC, PO, by inhalation or nasal routes) or in combination with sub-optimal doses of relevant chemotherapy (*e.g.*, cyclophosphamide, doxorubicin, etoposide). In one example, 5×10^6 SEMK2 cells (established from the bone marrow of a patient with acute lymphoblastic leukemia) that stably express luciferase are injected by tail vein in NOD-SCID, SCID-beige or NOD.IL2rg KO mice 3 hrs after they have been subjected to total body irradiation. Non-radiated mice may also be used for these studies. If left untreated, this form of leukemia is fatal in 3 weeks in this model. The leukemia is readily monitored, for example, by injecting the mice with D-luciferin (60 mg/kg) and imaging the anesthetized animals (*e.g.*, Xenogen In Vivo Imaging System, Caliper Life Sciences, Hopkinton, MA). Total body bioluminescence is quantified by integration of photonic flux (photons/sec) by Living Image Software (Caliper Life Sciences, Hopkinton, MA). Peptidomimetic macrocycles alone or in combination with sub-optimal doses of relevant chemotherapeutics agents are, for example, administered to leukemic mice (8-10 days after injection/day 1 of experiment, in bioluminescence range of 14-16) by tail vein or IP routes at doses ranging from 0.1mg/kg to 50 mg/kg for 7 to 21 days. Optionally, the mice are imaged throughout the experiment every other day and survival monitored daily for the duration of the experiment. Expired mice are optionally subjected to necropsy at the end of the experiment. Another animal model is implantation into NOD-SCID mice of DoHH2, a cell line derived from

human follicular lymphoma, that stably expresses luciferase. These *in vivo* tests optionally generate preliminary pharmacokinetic, pharmacodynamic and toxicology data.

Clinical Trials.

[00185] To determine the suitability of the peptidomimetic macrocycles of the invention for treatment of humans, clinical trials are performed. For example, patients diagnosed with cancer and in need of treatment are selected and separated in treatment and one or more control groups, wherein the treatment group is administered a peptidomimetic macrocycle of the invention, while the control groups receive a placebo, a known anti-cancer drug, or the standard of care. The treatment safety and efficacy of the peptidomimetic macrocycles of the invention can thus be evaluated by performing comparisons of the patient groups with respect to factors such as survival and quality-of-life. In this example, the patient group treated with a peptidomimetic macrocycle show improved long-term survival compared to a patient control group treated with a placebo or the standard of care.

Pharmaceutical Compositions and Routes of Administration

[00186] Methods of administration include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical by application to ears, nose, eyes, or skin.

[00187] The peptidomimetic macrocycles of the invention also include pharmaceutically acceptable derivatives or prodrugs thereof. A "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of an ester, pro-drug or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. For example, pharmaceutically acceptable derivatives may increase the bioavailability of the compounds of the invention when administered to a mammal (*e.g.*, by increasing absorption into the blood of an orally administered compound) or which increases delivery of the active compound to a biological compartment (*e.g.*, the brain or lymphatic system) relative to the parent species. Some pharmaceutically acceptable derivatives include a chemical group which increases aqueous solubility or active transport across the gastrointestinal mucosa.

[00188] In some embodiments, the peptidomimetic macrocycles of the invention are modified by covalently or non-covalently joining appropriate functional groups to enhance selective biological properties. Such modifications include those which increase biological penetration into a given biological compartment (*e.g.*, blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and alter rate of excretion.

[00189] Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (*e.g.*, sodium), alkaline earth metal (*e.g.*, magnesium), ammonium and N-(alkyl)₄⁺ salts.

[00190] For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers include either solid or liquid carriers. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which also acts

as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, *e.g.*, the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton PA.

[00191] In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[00192] Suitable solid excipients are carbohydrate or protein fillers include, but are not limited to sugars, including dextrose, lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

[00193] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. The term "parenteral" as used herein refers modes of administration including intravenous, intraarterial, intramuscular, intraperitoneal, intrasternal, and subcutaneous.

[00194] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

[00195] When the compositions of this invention comprise a combination of a peptidomimetic macrocycle and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. In some embodiments, the additional agents are administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents are part of a single dosage form, mixed together with the compounds of this invention in a single composition.

Methods of Use

[00196] In one aspect, the present invention provides novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to the natural ligand(s) of the proteins or peptides upon which the peptidomimetic macrocycles are modeled. For example, in the p53 MDM2 system, labeled stabilized peptidomimetic macrocycles based on the p53 is used in an MDM2 binding assay along with small molecules that competitively bind to MDM2. Competitive binding studies allow for rapid *in vitro* evaluation and determination of drug candidates specific for the p53/MDM2 system. Likewise in the BH3/BCL-X_L anti-apoptotic system labeled peptidomimetic macrocycles based on BH3 can be used in a BCL-X_L binding assay along with small molecules that competitively bind to BCL-X_L. Competitive binding studies allow for rapid *in vitro* evaluation and determination of drug candidates specific for the BH3/BCL-X_L system. The invention further provides for the generation of antibodies against the peptidomimetic macrocycles. In some embodiments, these antibodies specifically bind both the peptidomimetic macrocycle and the p53 or BH3 peptidomimetic precursors upon which the peptidomimetic macrocycles are derived. Such antibodies, for example, disrupt the p53/MDM2 or BH3/BCL-XL systems, respectively.

[00197] In other aspects, the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant (*e.g.*, insufficient or excessive) BCL-2 family member expression or activity (*e.g.*, extrinsic or intrinsic apoptotic pathway abnormalities). It is believed that some BCL-2 type disorders are caused, at least in part, by an abnormal level of one or more BCL-2 family members (*e.g.*, over or under expression), or by the presence of one or more BCL-2 family members exhibiting abnormal activity. As such, the reduction in the level and/or activity of the BCL-2 family member or the enhancement of the level and/or activity of the BCL-2 family member, is used, for example, to ameliorate or reduce the adverse symptoms of the disorder.

[00198] In another aspect, the present invention provides methods for treating or preventing hyperproliferative disease by interfering with the interaction or binding between p53 and MDM2 in tumor cells. These methods comprise administering an effective amount of a compound of the invention to a warm blooded animal, including a human, or to tumor cells containing wild type p53. In some embodiments, the administration of the compounds of the present invention induce cell growth arrest or apoptosis. In other or further embodiments, the present invention is used to treat disease and/or tumor cells comprising elevated MDM2 levels. Elevated levels of MDM2 as used herein refers to MDM2 levels greater than those found in cells containing more than the normal copy number (2) of *mdm2* or above about 10,000 molecules of MDM2 per cell as measured by ELISA and similar assays (Picksley *et al.* (1994), *Oncogene* 9, 2523 2529).

[00199] As used herein, the term "treatment" is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease.

[00200] In some embodiments, the peptidomimetics macrocycles of the invention is used to treat, prevent, and/or diagnose cancers and neoplastic conditions. As used herein, the terms "cancer", "hyperproliferative" and "neoplastic" refer to cells having the capacity for autonomous growth, *i.e.*, an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, *i.e.*, characterizing or constituting a disease state, or may be categorized as non-pathologic, *i.e.*, a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of breast, lung, liver, colon and ovarian origin. "Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair. Examples of cellular proliferative and/or differentiative disorders include cancer, *e.g.*, carcinoma, sarcoma, or metastatic disorders. In some embodiments, the peptidomimetics macrocycles are novel therapeutic agents for controlling breast cancer, ovarian cancer, colon cancer, lung cancer, metastasis of such cancers and the like.

[00201] Examples of cancers or neoplastic conditions include, but are not limited to, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, rectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer,

testicular cancer, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, or Kaposi sarcoma.

[00202] Examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term "hematopoietic neoplastic disorders" includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, *e.g.*, arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the diseases arise from poorly differentiated acute leukemias, *e.g.*, erythroblastic leukemia and acute megakaryoblastic leukemia. Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus (1991), *Crit Rev. Oncol./Hematol.* 11:267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Stenberg disease.

[00203] Examples of cellular proliferative and/or differentiative disorders of the breast include, but are not limited to, proliferative breast disease including, *e.g.*, epithelial hyperplasia, sclerosing adenosis, and small duct papillomas; tumors, *e.g.*, stromal tumors such as fibroadenoma, phyllodes tumor, and sarcomas, and epithelial tumors such as large duct papilloma; carcinoma of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma, and miscellaneous malignant neoplasms. Disorders in the male breast include, but are not limited to, gynecomastia and carcinoma.

[00204] Examples of cellular proliferative and/or differentiative disorders of the lung include, but are not limited to, bronchogenic carcinoma, including paraneoplastic syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcinoid, miscellaneous tumors, and metastatic tumors; pathologies of the pleura, including inflammatory pleural effusions, noninflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma.

[00205] Examples of cellular proliferative and/or differentiative disorders of the colon include, but are not limited to, non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcinoid tumors.

[00206] Examples of cellular proliferative and/or differentiative disorders of the liver include, but are not limited to, nodular hyperplasias, adenomas, and malignant tumors, including primary carcinoma of the liver and metastatic tumors.

[00207] Examples of cellular proliferative and/or differentiative disorders of the ovary include, but are not limited to, ovarian tumors such as, tumors of coelomic epithelium, serous tumors, mucinous tumors, endometrioid tumors, clear cell adenocarcinoma, cystadenofibroma, Brenner tumor, surface epithelial tumors; germ cell tumors such as mature (benign) teratomas, monodermal teratomas, immature malignant teratomas, dysgerminoma, endodermal sinus tumor, choriocarcinoma; sex cord-stromal tumors such as, granulosa-theca cell tumors, thecomafibromas, androblastomas, hil cell tumors, and gonadoblastoma; and metastatic tumors such as Krukenberg tumors.

[00208] In other or further embodiments, the peptidomimetics macrocycles described herein are used to treat, prevent or diagnose conditions characterized by overactive cell death or cellular death due to physiologic insult, etc. Some examples of conditions characterized by premature or unwanted cell death are or alternatively unwanted or excessive cellular proliferation include, but are not limited to hypocellular/hypoplastic, acellular/aplastic, or hypercellular/hyperplastic conditions. Some examples include hematologic disorders including but not limited to fanconi anemia, aplastic anemia, thalassemia, congenital neutropenia, myelodysplasia

[00209] In other or further embodiments, the peptidomimetics macrocycles of the invention that act to decrease apoptosis are used to treat disorders associated with an undesirable level of cell death. Thus, in some embodiments, the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat disorders such as those that lead to cell death associated with viral infection, *e.g.*, infection associated with infection with human immunodeficiency virus (HIV). A wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons, and the anti-apoptotic peptidomimetics macrocycles of the invention are used, in some embodiments, in the treatment of these disorders. Such disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) retinitis pigmentosa, spinal muscular atrophy, and various forms of cerebellar degeneration. The cell loss in these diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death. In addition, a number of hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death within the bone marrow. These disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses. Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis. In other or further embodiments, the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat all such disorders associated with undesirable cell death.

[00210] Some examples of immunologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to organ transplant rejection, arthritis, lupus, IBD, Crohn's disease, asthma, multiple sclerosis, diabetes, etc.

[00211] Some examples of neurologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to Alzheimer's Disease, Down's Syndrome, Dutch Type Hereditary Cerebral Hemorrhage Amyloidosis, Reactive Amyloidosis, Familial Amyloid Nephropathy with Urticaria and Deafness, Muckle-Wells Syndrome, Idiopathic Myeloma; Macroglobulinemia-Associated Myeloma, Familial Amyloid Polyneuropathy, Familial Amyloid Cardiomyopathy, Isolated Cardiac Amyloid, Systemic Senile Amyloidosis, Adult Onset Diabetes, Insulinoma, Isolated Atrial Amyloid, Medullary Carcinoma of the Thyroid, Familial Amyloidosis, Hereditary Cerebral Hemorrhage With Amyloidosis, Familial Amyloidotic Polyneuropathy, Scrapie, Creutzfeldt-Jacob Disease, Gerstmann Straussler-Scheinker Syndrome, Bovine Spongiform Encephalitis, a prion-mediated disease, and Huntington's Disease.

[00212] Some examples of endocrinologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to diabetes, hypothyroidism, hypopituitarism, hypoparathyroidism, hypogonadism, etc.


[00213] Examples of cardiovascular disorders (*e.g.*, inflammatory disorders) that are treated or prevented with the peptidomimetics macrocycles of the invention include, but are not limited to, atherosclerosis, myocardial infarction,

stroke, thrombosis, aneurism, heart failure, ischemic heart disease, angina pectoris, sudden cardiac death, hypertensive heart disease; non-coronary vessel disease, such as arteriolosclerosis, small vessel disease, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease; or a cardiovascular condition associated with interventional procedures ("procedural vascular trauma"), such as restenosis following angioplasty, placement of a shunt, stent, synthetic or natural excision grafts, indwelling catheter, valve or other implantable devices. Preferred cardiovascular disorders include atherosclerosis, myocardial infarction, aneurism, and stroke.

EXAMPLES

[00214] The following section provides illustrative examples of the present invention.

[00215] Example 1. Preparation of Alpha,Alpha-Disubstituted Amino Acids.



[00216] 1-Azido-n-iodo-alkanes **1**. To 1-iodo-n-chloro-alkane (8.2 mmol) in DMF (20 ml) was added sodium azide (1.2 eq.) and the reaction mixture was stirred at ambient temperature overnight. The reaction mixture was then diluted with diethyl ether and water. The organic layer was dried over magnesium sulfate and concentrated in vacuo to give 1-azido-n-chloro-alkane. The azide was diluted with acetone (40 ml) and sodium iodide (1.5 eq.) was added. The solution was heated at 60°C overnight. Afterwards, the reaction mixture was diluted with water and the product was extracted with diethyl ether. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The product **1** was purified by passing it through a plug of neutral alumina. Overall yield: 65 %. **1-Azido-3-iodo-propane**: ^1H NMR (CDCl_3) δ : 2.04 (q, 2H, CH_2); 3.25 (t, 2H, CH_2I); 3.44 (t, 2H, CH_2N_3). **1-Azido-5-iodo-pentane**: ^1H NMR (CDCl_3) δ : 1.50 (m, 2H, CH_2); 1.62 (m, 2H, CH_2); 1.86 (m, 2H, CH_2); 3.19 (t, 2H, CH_2I); 3.29 (t, 2H, CH_2N_3).


[00217] α Me-Sn-azide-Ni-S-BPB (R=Me), **2**. To **S-Ala-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **1** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **2** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **α Me-S3-azide-Ni-S-BPB (2, R=Me, n=3)**: M+H calc. 595.19, M+H obs. 595.16; ^1H NMR (CDCl_3) δ : 1.25 (s, 3H, Me (α Me-S3-azide)); 1.72-1.83 (m, 2H, CH_2); 2.07 (m, 2H, CH_2); 2.17 (m, 1H, CH_2); 2.48 (m, 2H, CH_2); 2.67 (m, 1H, CH_2); 3.27 (m, 2H, CH_2); 3.44 (m, 2H, CH_2); 3.64 (m, 1H, CH_α); 3.68 and 4.47 (AB system, 2H, CH_2 (benzyl)),

$J = 12.8\text{Hz}$); 6.62-6.64 (m, 2H); 7.05 (d, 1H); 7.13 (m, 1H); 7.30 (m, 2H); 7.28-7.32 (m, 2H); 7.38-7.42 (m, 3H); 7.47-7.50 (m, 2H); 8.01 (d, 1H); 8.07 (m, 2H).

[00218] Sn-azide-Ni-S-BPB (R=H), **2**. To **Gly-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **1** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **2** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **S3-azide-Ni-S-BPB (2, R=H, n=3)**: M+H calc. 581.17, M+H obs. 581.05; ^1H NMR (CDCl_3) δ : 1.72 (m, 2H, CH_2); 2.07 (m, 1H, CH_2); 2.16 (m, 3H, CH_2); 2.53 (m, 1H, CH_2); 2.75 (m, 1H, CH_2); 3.08 (m, 1H, CH_2); 3.22 (m, 1H, CH_2); 3.49 (m, 2H, CH_2); 3.59 (m, CH_α); 3.58 and 4.44 (AB system, 2H, CH_2 (benzyl)); 3.87 (m, CH_α); 6.64 (m, 2H); 6.96 (d, 1H); 7.14-7.19 (m, 2H); 7.35 (m, 2H); 7.51 (m, 4H); 8.04 (d, 2H); 8.12 (d, 1H).

[00219] Fmoc- α Me-Sn-azide-OH (R=Me), **3**. To a solution of 3N HCl/MeOH (1/1, 12 mL) at 70°C was added a solution of compound **2** (1.65 mmol) in MeOH (3 ml) dropwise. The starting material disappeared within 10-20 min. The green reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **3** was purified on normal phase using methanol and dichloromethane as eluents to give a viscous oil in 36 % overall yield for both steps. **Fmoc- α Me-S3-azide-OH (2, R=Me, n=3)**: M+H calc. 395.16, M+H obs. 395.12; ^1H NMR (CDCl_3) δ : 0.85 (bs, 1H, CH_2); 1.10 (bs, 1H, CH_2); 1.61 (s, 3H, Me (α Me-S3-azide)); 1.98 (bs, 1H, CH_2); 2.22 (bs, 1H, CH_2); 3.27 (bs, 2H, CH_2); 4.21 (m, 1H, CH); 4.42 (bs, 2H, CH_2); 5.53 (s, 1H, NH); 7.33 (m, 2H); 7.40 (m, 2H); 7.57 (m, 2H); 7.77 (d, 2H).

[00220] Fmoc-Sn-azide-OH (R=H), **3**. To a solution of 3N HCl/MeOH (1/1, 12 mL) at 70°C was added a solution of compound **2**, R=H (1.65 mmol) in MeOH (3 ml) dropwise. The starting material disappeared within 10-20 min. The green reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **3** was purified on normal phase using methanol and dichloromethane as eluents to give a viscous oil in 36 % overall yield for both steps. **Fmoc-S3-azide-OH (2, R=H, n=3)**: M+H calc. 381.15, M+H obs. 381.07; ^1H NMR (CDCl_3) 1.66 (bs, 2H, CH_2); 1.78 (bs, 1H, CH_2); 1.99 (bs, 1H, CH_2); 3.12 (1H, CH_α); 3.32 (bs, 2H, CH_2); 4.21 (m, 1H, CH); 4.43 (bs, 2H, CH_2); 5.37 (s, 1H, NH); 7.31 (m, 2H); 7.40 (m, 2H); 7.58 (m, 2H); 7.77 (d, 2H).



Scheme 11

[00221] (n+2)-Iodo-1-alkyne, **4**. To a solution of (n+2)-chloro-1-alkyne (47.8 mmol) in acetone (80 mL) was added sodium iodide (2 eq.). The reaction was heated at 60°C overnight. Afterwards, the reaction was diluted with water and the product was extracted with diethyl ether. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The product **5** was purified by passing it through a plug of neutral alumina. Yield: 92%. 5-Iodo-1-alkyne (n=3): ¹H NMR (CDCl₃) 2.00 (m, 3H, CH₂+CH); 2.34 (m, 2H, CH₂); 3.31 (t, 2H, CH₂).


[00222] αMe-S(n+2)-alkyne-Ni-S-BPB (R=Me), **5**. To **S-Ala-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **4** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **5** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **αMe-S5-alkyne-Ni-S-BPB (5, R=Me, n=3)**: M+H calc. 578.19, M+H obs. 578.17; ¹H NMR (CDCl₃) δ: 1.21 (s, 3H, Me (αMe-S5-alkyne)); 1.62 (1H, CH, acetylene); 1.77 (m, 1H, CH₂); 1.92 (m, 1H, CH₂); 2.05 (m, 2H, CH₂); 2.21 (m, 2H, CH₂); 2.33 (m, 1H, CH₂); 2.51 (m, 2H, CH₂); 2.70 (m, 1H, CH₂); 3.23 (m, 1H, CH_α); 3.44 (m, 1H, CH₂); 3.66 (m, 1H, CH₂); 3.69 and 4.49 (AB system, 2H, CH₂ (benzyl)); 6.64 (m, 2H); 7.05-7.13 (m, 2H); 7.27-7.31 (m, 2H); 7.40 (m, 3H); 7.47 (m, 2H); 8.00 (d, 1H); 8.06 (m, 2H).

[00223] S(n+2)-alkyne-Ni-S-BPB (R=H), **5**. To **Gly-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **4** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **5** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **S5-alkyne-Ni-S-BPB (5, R=H, n=3)**: M+H calc. 564.17, M+H obs. 564.15; ¹H NMR (CDCl₃) δ: 1.75 (m, 2H, CH₂); 1.95 (m, 1H, CH, acetylene); 2.06 (m, 2H, CH₂); 2.16 (m, 2H, CH₂); 2.30 (m, 1H, CH₂); 2.52 (m, 1H, CH₂); 2.77 (m, 1H, CH₂); 3.49 (m, 2H, CH₂); 3.59 (m, 1H, CH_α); 3.88 (m, 1H, CH_α); 3.58 and 4.43 (AB system, 2H, CH₂ (benzyl)); 6.63 (m, 2H); 6.96 (d, 1H); 7.14-7.19 (m, 2H); 7.34 (m, 2H); 7.44 (m, 1H); 7.49 (m, 3H); 8.05 (d, 2H); 8.12 (d, 1H).

[00224] Fmoc-αMe-S(n+2)-alkyne-OH (R=Me), **6**. To a solution of 3N HCl/MeOH (1/1, 18 mL) at 70°C was added a solution of compound **5**, R=Me (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10 min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in dioxane (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl

acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **6** was isolated after flash chromatography purification on silica gel using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 60% yield. **Fmoc- α Me-S5-alkyne-OH (6, R=Me, n=3)**: M+H calc. 378.16, M+H obs. 378.15; ^1H NMR (CDCl_3) δ : 1.42 (bs, 1H, CH_2); 1.54 (bs, 1H, CH_2); 1.61 (s, 3H, Me (α Me-S3-azide)); 1.96 (bs, 2H, CH_2); 2.20 (bs, 3H, CH_2 +CH acetylene); 4.21 (m, 1H, CH); 4.42 (bs, 2H, CH_2); 5.51 (s, 1H, NH); 7.32 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.77 (d, 2H).

[00225] Fmoc-S(n+2)-alkyne-OH (R=H), **6**. To a solution of 3N HCl/MeOH (1/1, 18 mL) at 70°C was added a solution of compound **5**, R=H (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10 min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in dioxane (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **6** was isolated after flash chromatography purification on silica gel using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 60% yield. **Fmoc-S5-alkyne-OH (6, R=H, n=3)**: M+H calc. 364.15, M+H obs. 364.14; ^1H NMR (CDCl_3) δ : 1.48–1.62 (m, 3H, CH_2); 1.81 (m, 1H, CH_2); 1.98 (m, 1H, CH_2); 1.99–2.11 (m, 1H, CH_2); 2.24 (m, 1H, CH acetylene); 4.21 (m, 1H, CH); 4.42 (bs, 2H, CH_2); 5.51 (s, 1H, NH); 7.32 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.77 (d, 2H).




[00226] α Me-S(n+2)-alkene-Ni-S-BPB (R=Me), **7**. To **S-Ala-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (2 eq.) was added 45 mL of DMF under argon. 1-Bromo-n-alkene (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **7** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **α Me-S5-alkene-Ni-S-BPB (7, R=Me, n=3)**: M+H calc. 580.20, M+H obs. 580.17; ^1H NMR (CDCl_3) δ : 1.23 (s, 3H, Me (α Me-S5-alkene)); 1.69 (m, 3H, CH_2); 2.0–2.14 (m, 5H, CH_2); 2.37–2.53 (m, 1H, CH_2); 2.69 (m, 1H, CH_2); 3.26 (m, 1H, CH_2); 3.43 (m, 1H, CH_2); 3.64 (m, 1H, CH_α); 3.70 and 4.50 (AB system, 2H, CH_2 (benzyl), $J=12.8\text{Hz}$); 5.0–5.10 (m, 2H, CH_2 alkene); 5.85 (m, 1H, CH alkene); 6.63 (m, 2H); 6.96 (d, 1H); 7.12 (m, 1H); 7.27–7.32 (m, 2H); 7.38–7.42 (m, 3H); 7.47–7.50 (m, 2H); 7.99 (d, 1H); 8.06 (m, 2H). **α Me-S8-alkene-Ni-S-BPB (7, R=Me, n=6)**: M+H calc. 622.25, M+H obs. 622.22; ^1H NMR (CDCl_3) δ : 1.24 (s, 3H, Me (α Me-S8-alkene)); 1.29–1.44 (m, 5H, CH_2); 1.56–1.74 (m, 3H, CH_2); 2.06 (m, 5H, CH_2); 2.32–2.51 (m, 2H, CH_2); 2.68 (m, 1H, CH_2); 3.28 (m, 1H, CH_2); 3.42 (m, 1H, CH_2); 3.62 (m,

1H, CH_α); 3.70 and 4.50 (AB system, 2H, CH₂ (benzyl), J= 12.8Hz); 4.92-5.02 (m, 2H, CH₂ alkene); 5.76-5.85 (m, 1H, CH alkene); 6.63 (m, 2H); 6.96 (d, 1H); 7.12 (m, 1H); 7.27-7.33 (m, 2H); 7.38-7.42 (m, 3H); 7.45-7.51 (m, 2H); 7.99 (d, 1H); 8.06 (m, 2H).

[00227] To **Gly-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (2 eq.) was added 45 mL of DMF under argon. 1-Bromo-n-alkene (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **7** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **S5-alkene-Ni-S-BPB (7, R=H, n=3)**: M+H calc. 566.19, M+H obs. 566.17; ¹H NMR (CDCl₃) δ: 1.69 (m, 3H, CH₂); 1.90-2.23 (m, 5H, CH₂); 2.52 (m, 1H, CH₂); 2.75 (m, 1H, CH₂); 3.44-3.49 (m, 2H, CH₂); 3.50 (m, 1H, CH_α); 3.90 (m, 1H, CH_α); 3.58 and 4.44 (AB system, 2H, CH₂ (benzyl)); 4.97 (m, 2H, CH₂ alkene); 5.72 (m, 1H, CH alkene); 6.64 (m, 2H); 6.91 (d, 1H); 7.14-7.20 (m, 2H); 7.34 (m, 2H); 7.44-7.49 (m, 4H); 8.04 (d, 2H); 8.12 (d, 1H).

[00228] Fmoc-αMe-S(n+2)-alkene-OH (R=Me), **8**. To a solution (18 mL) of 1/1 3N HCl/MeOH at 70°C was added a solution of compound **7**, R=Me (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10 min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **8** was isolated after flash chromatography purification on normal phase using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 75% yield. **Fmoc-αMe-S5-alkene-OH (8, R=Me, n=3)**: M+H calc. 380.18, M+H obs. 380.16; ¹H NMR (CDCl₃) δ: 1.26–1.41 (m, 3H, CH₂); 1.61 (bs, 3H, αMe); 1.86 (bs, 1H); 2.05 (m, 2H, CH₂); 4.22 (m, 1H, CH (Fmoc)); 4.40 (bs, 2H, CH₂ (Fmoc)); 4.97 (m, 2H, CH₂ alkene); 5.53 (bs, 1H, NH); 5.75 (m, 1H, CH alkene); 7.29-7.33 (m, 2H); 7.38-7.42 (m, 2H); 7.59 (d, 2H); 7.76 (d, 2H). **Fmoc-αMe-S8-alkene-OH (8, R=Me, n=6)**: M+H calc. 422.23, M+H obs. 422.22; ¹H NMR (CDCl₃) δ: 1.28 (m, 9H, CH₂); 1.60 (bs, 3H, αMe); 1.83 (bs, 1H); 2.01 (m, 2H, CH₂); 4.22 (m, 1H, CH (Fmoc)); 4.39 (bs, 2H, CH₂ (Fmoc)); 4.90-5.00 (m, 2H, CH₂ alkene); 5.49 (bs, 1H, NH); 5.75-5.82 (m, 1H, CH alkene); 7.29-7.33 (m, 2H); 7.38-7.42 (m, 2H); 7.59 (d, 2H); 7.77 (d, 2H).


[00229] Fmoc-S(n+2)-alkene-OH (R=H), **8**. To a solution (18 mL) of 1/1 3N HCl/MeOH at 70°C was added a solution of compound **7**, R=H (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10 min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **8** was isolated after flash chromatography purification on normal phase using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 75% yield. **Fmoc-S5-alkene-OH (8, R=H, n=3)**: M+H calc. 365.16, M+H obs. 365.09; ¹H NMR (CDCl₃) δ: 1.48 (m, 2H, CH₂); 1.72 (m, 1H); 1.91 (m, 1H, CH₂); 2.09 (m, 2H); 4.23 (m, 1H, CH (Fmoc)); 4.42 (m, 2H, CH₂ (Fmoc)); 5.00 (m, 3H, CH₂ alkene+ CH_α); 5.22 (d, 1H, NH); 5.76 (m, 1H, CH alkene); 7.31 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.76 (d, 2H).



[00230] α Me-S-Ser-Ni-S-BPB, **9**. To a solution of KOH (7.5 eq.) in methanol (20 mL) were added **S-Ala-Ni-S-BPB** (4 mmol) and paraformaldehyde (20 eq.) at room temperature. The reaction mixture was stirred overnight and neutralized with acetic acid. Then water was added to precipitate a mixture of diastereoisomers. Precipitation was completed overnight. The precipitate was filtered off, washed with water and dried under vacuum. The diastereoisomer (S, S), **9** were isolated by flash chromatography on normal phase using acetone and dichloromethane as eluents. The compound **9** is a red solid (yield 33%). M+H calc. 542.15, M+H obs. 542.09; ^1H NMR (CDCl_3) δ : 1.05 (s, 3H, Me (serine)); 1.98 (m, 2H, CH_2); 2.39 (m, 1H, CH_2); 2.65 (m, 1H, CH_2); 3.41 (m, 2H, CH_2); 3.44 (m, 1H, CH_α); 3.69 (m, 2H, CH_2 (serine)); 3.58 and 4.37 (AB system, 2H, CH_2 (benzyl), $J = \text{Hz}$); 6.60 (m, 1H); 6.67 (dd, 1H); 7.1 (m, 1H); 7.17 (d, 1H); 7.27 (m, 2H); 7.35-7.47 (m, 5H); 7.95 (dd, 1H); 8.09 (m, 2H).


[00231] Boc- α Me-L-Ser-OH, **10**. To a solution of 3N HCl/MeOH (1/1, 6 ml) at 70°C was added 0.86 mmol of compound **10** (dissolved in 2 ml MeOH). The solution was stirred at 70°C for 15-20 min till the red color disappeared. The green solution was then concentrated to dryness. Water (3 ml) was added dropwise to precipitate the HCl salt of BPB auxiliary. The filtrate was removed and the white solid was washed twice with 1.5 ml water each (85% recovery of BPB, HCl). To the combined filtrates were added 8 eq. of solid Na_2CO_3 , followed by 2 eq EDTA disodium salt. The reaction was stirred at room temperature for 1 h. The solution became blue. Then it was cooled to 0°C with ice /water bath and 1.1 eq. of Boc_2O (dissolved in 6 ml dioxane) was added dropwise. The reaction was stirred overnight. Afterwards it was diluted with diethyl ether and water. The water layer was extracted once with diethyl ether. The aqueous layer was acidified with 1N HCl to pH=3 and washed with diethyl ether (3x). The combined organic layers were washed with brine, dried over MgSO_4 and concentrated in vacuo. The Boc protecting amino acid was used with any further purification for the next step. M+H calc. 260.14, M+H obs. 260.12; ^1H NMR (CDCl_3) δ : 1.45 (s, 9H, Boc); 1.50 (s, 3H, α Me (serine)); 3.86 (m, 2H, CH_2); 5.48 (s, 1H, NH).

[00232] Fmoc- α Me-L-Ser(OAllyl)-OH ($n=1$), **11**. To a solution of **10** (2 mmol) in DMF (10 ml) at 0°C were added NaH (2 eq.) and allyl bromide (1 eq.). The solution was stirred at 0°C for 2h. The reaction was diluted with ethyl acetate and water. The organic layer was washed with brine, dried over MgSO_4 and concentrated in vacuo. The crude material was dissolved in dichloromethane (6 mL) and TFA (3 mL) was added to the solution. The reaction was stirred for 1h. The solution was then concentrated to dryness. Finally the crude material was dissolved in solution of aqueous NaHCO_3 and acetone (1/1, 20 mL) and FmocOSu (1.1 eq.) was added dropwise at 0°C. The reaction was stirred overnight. Afterwards the solution mixture was diluted with diethyl ether and water. The organic layer were washed with brine, dried over MgSO_4 and concentrated in vacuo. The desired product **11** was isolated after flash chromatography purification on silica gel using methanol and dichloromethane as eluents to give viscous oil in 49% yield. M+H calc. 382.16, M+H obs. 382.14; ^1H NMR (CDCl_3) δ : 1.62 (s, 3H, α Me (serine)); 3.80 (bs, 2H, CH_2); 4.02 (bs, 2H, CH_2); 4.24 (m, 1H, CH); 4.40 (bs, 2H, CH_2); 5.23 (m, 2H, CH_2); 5.74 (s, 1H, NH); 5.84 (m, 1H, CH); 7.32 (m, 2H); 7.40 (m, 2H); 7.60 (d, 2H); 7.76 (d, 2H).



Scheme 14

[00233] Fmoc-L-Ser(Oallyl)-OH, **12**. To a solution of **Boc-L-Serine** (2 mmol) in DMF (10 mL) at 0°C were added NaH (2 eq.) and allyl bromide (1 eq.). The solution was stirred at 0°C for 2h. The reaction was diluted with ethyl acetate and water. The organic layer was washed with brine, dried over MgSO_4 and concentrated in vacuo. The crude material was dissolved in dichloromethane (6 mL) and TFA (3 mL) was added to the solution. The reaction was stirred for 1h. The solution was then concentrated to dryness. Finally the crude material was dissolved in solution of aqueous NaHCO_3 and acetone (1/1, 20 mL) and FmocOSu (1.1 eq.) was added dropwise at 0°C . The reaction was stirred overnight. Afterwards the solution mixture was diluted with diethyl ether and water. The organic layer were washed with brine, dried over MgSO_4 and concentrated in vacuo. The desired product **12** was isolated after flash chromatography purification on silica gel using methanol and dichloromethane as eluents to give viscous oil in 69% yield. M+H calc. 367.14, M+H obs. 367.12; ^1H NMR (CDCl_3) δ : 3.64 (m, 1H, CH_α); 3.88 (m, 1H, CH Fmoc); 3.96 (m, 2H, CH_2 Fmoc); 4.17 (m, 1H, CH_2); 4.36 (m, 2H, CH_2); 4.48 (m, 1H, CH_2); 5.14 (m, 2H, CH_2); 5.60 (d, 1H, NH); 5.79 (m, 1H, CH); 7.24 (m, 2H); 7.33 (m, 2H); 7.54 (m, 2H); 7.68 (d, 2H).



Scheme 15

[00234] α Me-Rn-azide-Ni-R-BPB (R=Me), **13**. To **R-Ala-Ni-R-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **1** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **13** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **α Me-R5-azide-Ni-R-BPB (13, R=Me, n=5)**: M+H calc. 623.22, M+H obs. 623.19; ^1H NMR (CDCl_3) δ : 1.24 (s, 3H, Me (α Me-R5-azide)); 1.33 (m, 2H, CH_2); 1.63 (m, 4H, CH_2); 2.05 (m, 3H, CH_2); 2.32 (m, 1H, CH_2); 2.48 (m, 1H, CH_2); 2.67 (m, 1H, CH_2); 3.28 (m, 3H, CH_2); 3.43 (m, 1H, CH_2); 3.63 (m, 1H, CH_α); 3.71 and 4.50 (AB system,


2H, CH₂ benzyl); 6.64 (m, 2H); 6.95 (d, 1H); 7.13 (m, 1H); 7.28-7.32 (m, 2H); 7.38-7.42 (m, 3H); 7.47-7.50 (m, 2H); 7.99 (d, 1H); 8.06 (d, 2H). **αMe-R6-azide-Ni-R-BPB (13, R=Me, n=6)**: M+H calc. 637.24, M+H obs. 637.22; ¹H NMR (CDCl₃) δ: 1.24 (s, 3H, Me (αMe-R6-azide)); 1.33 (m, 2H, CH₂); 1.48 (m, 2H, CH₂); 1.63 (m, 4H, CH₂); 2.05 (m, 3H, CH₂); 2.32 (m, 1H, CH₂); 2.48 (m, 1H, CH₂); 2.67 (m, 1H, CH₂); 3.28 (m, 3H, CH₂); 3.43 (m, 1H, CH₂); 3.63 (m, 1H, CH_α); 3.71 and 4.50 (AB system, 2H, CH₂ benzyl); 6.64 (m, 2H); 6.95 (d, 1H); 7.13 (m, 1H); 7.28-7.32 (m, 2H); 7.38-7.42 (m, 3H); 7.47-7.50 (m, 2H); 7.99 (d, 1H); 8.06 (d, 2H).

[00235] R_n-azide-Ni-R-BPB (R=H), **13**. To **Gly-Ni-R-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. The compound **1** (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **13** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **R5-azide-Ni-R-BPB (13, R=H, n=5)**: M+H calc. 609.20, M+H obs. 609.18; δ: 1.18 (m, 2H, CH₂); 1.52 (m, 4H, CH₂); 2.06 (m, 3H, CH₂); 2.17 (m, 1H, CH₂); 2.53 (m, 1H, CH₂); 2.74 (m, 1H, CH₂); 3.20 (m, 2H, CH₂); 3.48 (m, 2H, CH₂); 3.55 (m, 1H, CH_α); 3.90 (m, 1H, CH_α); 3.58 and 4.44 (AB system, 2H, CH₂ benzyl); 6.63 (m, 2H); 6.92 (d, 1H); 7.11-7.21 (m, 2H); 7.27 (m, 1H); 7.32-7.36 (m, 2H); 7.46-7.50 (m, 3H); 8.04 (d, 2H); 8.11 (d, 1H). **R6-azide-Ni-R-BPB (13, R=H, n=6)**: M+H calc. 623.22, M+H obs. 623.19; ¹H NMR (CDCl₃) δ: 1.16 (m, 2H, CH₂); 1.32 (m, 2H, CH₂); 1.54 (m, 4H, CH₂); 2.05 (m, 3H, CH₂); 2.16 (m, 1H, CH₂); 2.53 (m, 1H, CH₂); 2.74 (m, 1H, CH₂); 3.22 (m, 2H, CH₂); 3.48 (m, 2H, CH₂); 3.58 (m, 1H, CH_α); 3.90 (m, 1H, CH_α); 3.59 and 4.44 (AB system, 2H, CH₂ benzyl); 6.63 (m, 2H); 6.92 (d, 1H); 7.11-7.21 (m, 2H); 7.27 (m, 1H); 7.32-7.36 (m, 2H); 7.45 (m, 1H); 7.50 (m, 2H); 8.04 (d, 2H); 8.11 (d, 1H).

[00236] Fmoc-αMe-R_n-azide-OH (R=Me), **14**. To a solution of 3N HCl/MeOH (1/1, 12 mL) at 70°C was added a solution of compound **13, R=Me** (1.65 mmol) in MeOH (3 ml) dropwise. The starting material disappeared within 10-20 min. The green reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **14** was purified on normal phase using methanol and dichloromethane as eluents to give a viscous oil in 36 % overall yield for both steps. **Fmoc-αMe-R5-azide-OH (14, R=Me, n=5)**: M+H calc. 423.20, M+H obs. 423.34; ¹H NMR (CDCl₃) δ: 0.90 (bs, 2H, CH₂); 1.36 (bs, 2H, CH₂); 1.56 (m, 2H); 1.60 (bs, 3H, Me (αMe-R5-azide)); 1.86 (bs, 1H, CH₂); 2.15 (bs, 1H, CH₂); 3.23 (bs, 2H, CH₂); 4.22 (m, 1H, CH Fmoc); 4.40 (bs, 2H, CH₂ Fmoc); 5.51 (bs, 1H, NH); 7.32 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.78 (d, 2H). **Fmoc-αMe-R6-azide-OH (14, R=Me, n=6)**: M+H calc. 437.21, M+H obs. 437.31; ¹H NMR (CDCl₃) δ: 0.90 (bs, 2H, CH₂); 1.32 (bs, 4H, CH₂); 1.56 (m, 2H); 1.61 (bs, 3H, Me (αMe-R6-azide)); 1.84 (bs, 1H, CH₂); 2.13 (bs, 1H, CH₂); 3.23 (t, 2H, CH₂); 4.22 (m, 1H, CH Fmoc); 4.39 (bs, 2H, CH₂ Fmoc); 5.51 (bs, 1H, NH); 7.32 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.77 (d, 2H).

[00237] Fmoc-R_n-azide-OH (R=H), **14**. To a solution of 3N HCl/MeOH (1/1, 12 mL) at 70°C was added a solution of compound **13, R=H** (1.65 mmol) in MeOH (3 ml) dropwise. The starting material disappeared within 10-20 min. The green reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl

acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **14** was purified on normal phase using methanol and dichloromethane as eluents to give a viscous oil in 36 % overall yield for both steps. **Fmoc-R5-azide-OH** (**14**, R=H, n=5): M+H calc. 409.18, M+H obs. 409.37; ^1H NMR (CDCl_3) δ : 1.29 (bs, 2H, CH_2); 1.40 (bs, 2H, CH_2); 1.60 (m, 2H); 1.72 (bs, 1H, CH_2); 1.90 (bs, 1H, CH_2); 3.26 (m, 2H, CH_2); 4.23 (m, 1H, CH Fmoc); 4.41 (m, 3H, CH_2 Fmoc + CH_α); 5.30 (d, 1H, NH); 7.32 (m, 2H); 7.40 (m, 2H); 7.59 (d, 2H); 7.78 (d, 2H). **Fmoc-R6-azide-OH** (**14**, R=H, n=6): M+H calc. 423.20, M+H obs. 423.34; NMR (CDCl_3) δ : 1.37 (bs, 6H, CH_2); 1.59 (bs, 2H, CH_2); 1.70 (bs, 1H, CH_2); 1.90 (bs, 1H, CH_2); 3.25 (m, 2H, CH_2); 4.23 (m, 1H, CH Fmoc); 4.41 (m, 3H, CH_2 Fmoc + CH_α); 5.24 (d, 1H, NH); 7.32 (m, 2H); 7.39 (m, 2H); 7.59 (m, 2H); 7.76 (d, 2H).




[00238] α Me-R(n+2)-alkene-Ni-R-BPB (R=Me), **15**. To **R-Ala-Ni-R-BPB** (10.0 mmol) and KO-*t*Bu (2 eq.) was added 45 mL of DMF under argon. 1-Bromo-n-alkene (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **15** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **α Me-R8-alkene-Ni-R-BPB** (**7**, R=Me, n=6): M+H calc. 622.25, M+H obs. 622.22; ^1H NMR (CDCl_3) δ : 1.24 (s, 3H, Me (α Me-S8-alkene)); 1.29-1.44 (m, 5H, CH_2); 1.56-1.74 (m, 3H, CH_2); 2.06 (m, 5H, CH_2); 2.32-2.51 (m, 2H, CH_2); 2.68 (m, 1H, CH_2); 3.28 (m, 1H, CH_2); 3.42 (m, 1H, CH_2); 3.62 (m, 1H, CH_α); 3.70 and 4.50 (AB system, 2H, CH_2 (benzyl), J= 12.8Hz); 4.92-5.02 (m, 2H, CH_2 alkene); 5.76-5.85 (m, 1H, CH alkene); 6.63 (m, 2H); 6.96 (d, 1H); 7.12 (m, 1H); 7.27-7.33 (m, 2H); 7.38-7.42 (m, 3H); 7.45-7.51 (m, 2H); 7.98 (d, 1H); 8.06 (d, 2H).

[00239] R(n+2)-alkene-Ni-R-BPB (R=H), **15**. To **Gly-Ni-R-BPB** (10.0 mmol) and KO-*t*Bu (2 eq.) was added 45 mL of DMF under argon. 1-Bromo-n-alkene (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction was stirred at ambient temperature for 1h. The reaction was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **15** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 55 % yield. **R8-alkene-Ni-R-BPB** (**15**, R=H, n=6): M+H calc. 608.23, M+H obs. 608.21; ^1H NMR (CDCl_3) δ : 1.14 (m, 2H, CH_2); 1.30 (m, 4H, CH_2); 1.61 (m, 2H, CH_2); 1.92-2.16 (m, 6H, CH_2); 2.52 (m, 1H, CH_2); 2.75 (m, 1H, CH_2); 3.44-3.52 (m, 2H, CH_2); 3.58 (m, 1H, CH_α); 3.91 (m, 1H, CH_α); 3.58 and 4.44 (AB system, 2H, CH_2 (benzyl)); 4.92-5.00 (m, 2H, CH_2 alkene); 5.78 (m, 1H, CH alkene); 6.63 (m, 2H); 6.91 (d, 1H); 7.13-7.18 (m, 2H); 7.24 (m, 1H); 7.34 (m, 2H); 7.38-7.49 (m, 3H); 8.03 (d, 2H); 8.12 (d, 1H).

[00240] Fmoc- α Me-R(n+2)-alkene-OH (R=Me), **16**. To a solution (18 mL) of 1/1 3N HCl/MeOH at 70°C was added a solution of compound **15**, R=Me (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10

min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **16** was isolated after flash chromatography purification on normal phase using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 75% yield. **Fmoc- α Me-R8-alkene-OH (16, R=Me, n=6)**: M+H calc. 422.23, M+H obs. 422.22; ^1H NMR (CDCl_3) δ : 1.28 (m, 8H, CH_2); 1.60 (s, 3H, αMe); 1.83 (m, 1H, CH_2); 2.01 (m, 2H, CH_2); 2.11 (m, 1H, CH_2); 4.22 (m, 1H, CH (Fmoc)); 4.39 (m, 2H, CH_2 (Fmoc)); 4.90-5.00 (m, 2H, CH_2 alkene); 5.49 (bs, 1H, NH); 5.75-5.82 (m, 1H, CH alkene); 7.29-7.33 (m, 2H); 7.38-7.42 (m, 2H); 7.59 (d, 2H); 7.77 (d, 2H).


[00241] Fmoc-R(n+2)-alkene-OH (R=H), **16**. To a solution (18 mL) of 1/1 3N HCl/MeOH at 70°C was added a solution of compound **15**, R=H (2.4 mmol) in MeOH (4 ml) dropwise. The starting material disappeared within 5-10 min. The green solution was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (24 ml) cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (24 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **16** was isolated after flash chromatography purification on normal phase using methanol and dichloromethane as eluents to give viscous oil that solidifies upon standing in 75% yield. **Fmoc-R8-alkene-OH (16, R=H, n=6)**: M+H calc. 407.21, M+H obs. 407.19; ^1H NMR (CDCl_3) δ : 1.32 (m, 8H, CH_2); 1.71 (m, 1H); 1.89 (m, 1H, CH_2); 2.03 (m, 2H); 4.23 (m, 1H, CH (Fmoc)); 4.42 (m, 2H, CH_2 (Fmoc)); 4.96 (m, 2H, CH_2 alkene+ CH_α); 5.20 (d, 1H, NH); 5.79 (m, 1H, CH alkene); 7.32 (m, 2H); 7.41 (m, 2H); 7.59 (m, 2H); 7.77 (d, 2H).




[00242] $\alpha\text{Me-Phe-Ni-S-BPB}$, **17**. To **S-Ala-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. Benzyl bromide (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **17** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 60 % yield. **$\alpha\text{Me-Phe-Ni-S-BPB}$ (17)**: M+H calc. 602.19, M+H obs. 602.18; ^1H NMR (CDCl_3) δ : 1.17 (s, 3H, Me ($\alpha\text{Me-Phe}$)); 1.57 (m, 1H, CH_2); 1.67 (m, 1H, CH_2); 1.89 (m, 1H, CH_2); 2.06 (m, 1H, CH_2); 2.24 (m, 2H, CH_2); 3.05 (m, 1H); 3.18 (s, 2H); 3.26 (m, 1H); 3.56 and 4.31 (AB system, 2H, CH_2 (benzyl), $J = 12.8\text{Hz}$); 6.64 (m, 2H); 6.94 (d, 1H); 7.12 (m, 1H); 7.20 (m, 1H); 7.20-7.40 (m, 10H); 7.43 (m, 2H); 8.01 (d, 2H); 8.13 (m, 1H).

[00243] Fmoc- $\alpha\text{Me-Phe-OH}$, **18**. To a solution of 3N HCl/MeOH (1/1, 15 mL) at 70°C was added a solution of compound **17** (2.1 mmol) in MeOH (5 ml) dropwise. The starting material disappeared within 10-20 min. The green

reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na_2CO_3 (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **18** was purified on normal phase using acetone and dichloromethane as eluents to give a white foam in 52 % overall yield for both steps. **Fmoc- α Me-Phe-OH (18)**: M+H calc. 402.16, M+H obs. 402.12; ^1H NMR (CDCl_3) 1.64 (s, 3H, Me); 3.35 (bs, 2H, CH_2); 4.26 (m, 1H, CH); 4.48 (bs, 2H, CH_2); 5.35 (s, 1H, NH); 7.08 (m, 2H); 7.19 (m, 3H); 7.32 (m, 2H); 7.42 (m, 2H); 7.59 (m, 2H); 7.78 (d, 2H).



[00244] Fmoc- α Me-Arg(Boc) $_2$ -OH, **19**. To a solution of compound **3** (2.3 mmol) in isopropanol (20 mL) was added 10% palladium on activated carbon. The suspension was stirred under hydrogen at atmospheric pressure overnight. The solution was filtrated on celite and was then concentrated in vacuo. The crude residue was dissolved in THF (16 ml) and Pyrazole(Boc) $_2$ (1.1 eq.) was added and the reaction was stirred overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **19** was purified on normal phase using acetone and dichloromethane as eluents to give a white foam in 40 % overall yield for both steps. **Fmoc- α Me-Arg(Boc) $_2$ -OH (19)**: M+H calc. 611.30, M+H obs. 611.15; ^1H NMR (CDCl_3) 1.47 and 1.48 (2s, 18H, 2Boc); 1.48 (m, 2H, CH_2); 1.63 (s, 3H, CH_3); 1.84 (m, 1H, CH_2); 2.35 (m, 1H, CH_2); 3.34 (m, 2H, CH_2); 4.23 (m, 1H, CH); 4.34 and 4.42 (2m, 2H, CH_2); 5.92 (s, 1H, NH); 7.32 (m, 2H); 7.39 (m, 2H); 7.60 (d, 2H); 7.76 (d, 2H), 8.46 (bs, 1H, NH).



[00245] α Me-Tyr(OMe)-Ni-S-BPB, **20**. To **S-Ala-Ni-S-BPB** (10.0 mmol) and KO-*t*Bu (1.5 eq.) was added 45 mL of DMF under argon. 4-Methoxybenzyl chloride (1.5 eq.) in solution of DMF (4.0 mL) was added via syringe. The reaction mixture was stirred at ambient temperature for 1h. The solution was then quenched with 5 % aqueous acetic acid and diluted with water. The oily product was collected by filtration and washed with water. The desired product **20** was purified by flash chromatography on normal phase using acetone and dichloromethane as eluents to give a red solid in 60 % yield. **α Me-Tyr(OMe)-Ni-S-BPB (20)**: M+H calc. 632.20, M+H obs. 632.18; ^1H NMR (CDCl_3) δ : 1.12 (s, 3H, Me (α Me-Tyr(OMe))); 1.57 (m, 1H, CH_2); 1.90(m, 1H, CH_2); 2.05 (m, 1H, CH_2); 2.23 (m, 2H, CH_2); 3.08 (m, 3H, CH_2); 3.26 (m, 1H); 3.80 (s, 3H, OMe); 3.52 and 4.27 (AB system, 2H, CH_2 (benzyl), $J = 12.8\text{Hz}$); 6.58 (m, 2H); 6.96 (m, 3H); 7.09 (m, 1H); 7.17 (m, 1H); 7.27-7.32 (m, 5H); 7.36 (m, 1H); 7.45 (m, 2H); 7.99 (d, 2H); 8.09 (d, 1H).

[00246] Fmoc- α Me-Tyr(OMe)-OH, **21**. To a solution of 3N HCl/MeOH (1/1, 15 mL) at 70°C was added a solution of compound **20** (2.1 mmol) in MeOH (5 ml) dropwise. The starting material disappeared within 10-20 min. The green reaction mixture was then concentrated in vacuo. The crude residue was diluted with 10 % aqueous Na₂CO₃ (16 ml) and cooled to 0°C with an ice bath. Fmoc-OSu (1.1 eq.) dissolved in acetone (16 ml) was added and the reaction was allowed to warm up to ambient temperature with stirring overnight. Afterwards, the reaction was diluted with ethyl acetate and 1 N HCl. The organic layer was washed with 1 N HCl (3x). The organic layer was then dried over magnesium sulfate and concentrated in vacuo. The desired product **21** was purified on normal phase using acetone and dichloromethane as eluents to give a white foam in 56 % overall yield for both steps. **Fmoc- α Me-Tyr(OMe)-OH (21)**: M+H calc. 432.17, M+H obs. 432.12; ¹H NMR (CDCl₃) 1.63 (s, 3H, Me); 3.27 (m, 2H, CH₂); 4.25 (m, 1H, CH); 4.46 (bs, 2H, CH₂); 5.35 (s, 1H, NH); 6.75 (d, 2H); 6.97 (bs, 2H); 7.32 (m, 2H); 7.41 (m, 2H); 7.59 (m, 2H); 7.77 (d, 2H).

[00247] The non-natural amino acids (R and S enantiomers of the 5-carbon olefinic amino acid and the S enantiomer of the 8-carbon olefinic amino acid) were characterized by nuclear magnetic resonance (NMR) spectroscopy (Varian Mercury 400) and mass spectrometry (Micromass LCT). Peptide synthesis was performed either manually or on an automated peptide synthesizer (Applied Biosystems, model 433A), using solid phase conditions, rink amide AM resin (Novabiochem), and Fmoc main-chain protecting group chemistry. For the coupling of natural Fmoc-protected amino acids (Novabiochem), 10 equivalents of amino acid and a 1:1:2 molar ratio of coupling reagents HBTU/HOBt (Novabiochem)/DIEA were employed. Non-natural amino acids (4 equiv) were coupled with a 1:1:2 molar ratio of HATU (Applied Biosystems)/HOBt/DIEA, or as further described below. Olefin metathesis was performed in the solid phase using 10 mM Grubbs catalyst (Blackwell et al. 1994 supra) (Strem Chemicals) dissolved in degassed dichloromethane and reacted for 2 hours at room temperature. Isolation of metathesized compounds was achieved by trifluoroacetic acid-mediated deprotection and cleavage, ether precipitation to yield the crude product, and high performance liquid chromatography (HPLC) (Varian ProStar) on a reverse phase C18 column (Varian) to yield the pure compounds. Chemical composition of the pure products was confirmed by LC/MS mass spectrometry (Micromass LCT interfaced with Agilent 1100 HPLC system) and amino acid analysis (Applied Biosystems, model 420A).

[00248] Example 2. Synthesis of Peptidomimetic Macrocycles of the invention.

[00249] α -helical BID peptidomimetic macrocycles were synthesized, purified and analyzed as previously described (Walensky et al (2004) Science 305:1466-70; Walensky et al (2006) Mol Cell 24:199-210, all of which are incorporated by reference) and as indicated below. The following macrocycles were used in this study:

Macro-cycle	WT Sequence	Sequence	Calculated m/z (M+H)	Calculated m/z (M+3H)	Found m/z (M+3H)
SP-1	BIM-BH3	Ac-RWIAQALR\$IGD\$FNAFYARR-NH ₂	2615.45	872.49	872.64
SP-2	BIM-BH3	Ac-RWIAQALR\$IGD\$FNA(Amf)YARR-NH ₂	2629.46	877.16	877.43
SP-3	BIM-BH3	Ac-RWIAQALR\$IGD\$FNAFYA(Amr)R-NH ₂	2629.46	877.16	877.43
SP-4	BIM-BH3	Ac-IWIAQALR\$IGD\$FNAYYARR-NH ₂	2588.43	863.48	863.85
SP-5	BIM-BH3	Ac-IWIAQALR\$r5IGDStFNA\$YARR-NH ₂	2590.47	864.16	864.81
SP-6	BIM-BH3	Ac-IWIAQALR\$IGDStFNA\$r5YARR-NH ₂	2590.47	864.16	864.68

[00250] Alpha, alpha-disubstituted non-natural amino acids containing olefinic side chains were synthesized according to Williams et al. (1991) J. Am. Chem. Soc. 113:9276; and Schafmeister et al. (2000) J. Am. Chem Soc. 122:5891. Peptidomimetic macrocycles were designed by replacing two naturally occurring amino acids (see above) with the

corresponding synthetic amino acids. Substitutions were made at the i and i+4 and i to i+7 positions as indicated. Peptidomimetic macrocycles were generated by solid phase peptide synthesis followed by crosslinking of the synthetic amino acids via the reactive moieties of their side chains. The control sequences for BID and BIM peptidomimetic macrocycles are shown above. In the above table, where two sequences are indicated for a single macrocycle name, each sequence represents an isomer obtained as a result of the crosslinking reaction.

[00251] In the above sequences, the following nomenclature is used:

\$	Cis olefin i to i+4 crosslink, formed by alpha-Me S5 olefin amino acid
\$r5	Cis olefin i to i+4 crosslink, formed by alpha-Me R5 olefin amino acid
St	Tandem cis olefin i to i+4 crosslink; two crosslinks originate from aminoacid noted as "St"
Amf	Alpha-Me Phenylalanine amino acid
Amr	Alpha-Me Arginine amino acid
Ac	Acetyl (acetylated N-terminus)
NH2	Amide (amidated C-terminus)
Nle	Norleucine
Aib	2-aminoisobutyric acid

Example 3. Cell Viability Assays of Tumor Cell Lines Treated With Peptidomimetic Macrocycles of the Invention.

[00252] Tumor cell lines are grown in specific serum-supplemented media (growth media) as recommended by ATCC and the NCI. A day prior to the initiation of the study, cells were plated at optimal cell density (15,000 to 25,000 cells/well) in 200 μ l growth media in microtiter plates. The next day, cells were washed twice in serum-free/phenol red-free RPMI complete media (assay buffer) and a final volume of 100 μ l assay buffer was added to each well. Human peripheral blood lymphocytes (hPBLs) were isolated from Buffy coats (San Diego Blood Bank) using Ficoll-Paque gradient separation and plated on the day of the experiment at 25,000 cells/well.

[00253] Peptidomimetic macrocycles were diluted from 1 mM stocks (100% DMSO) in sterile water to prepare 400 μ M working solutions. The macrocycles and controls were then diluted 10 or 40 fold or alternatively serially two-fold diluted in assay buffer in dosing plates to provide concentrations of either 40 and 20 μ M or between 1.2 and 40 μ M, respectively. 100 μ L of each dilution was then added to the appropriate wells of the test plate to achieve final concentrations of the polypeptides equal to 20 or 5 μ M, or between 0.6 to 20 μ M, respectively. Controls included wells without polypeptides containing the same concentration of DMSO as the wells containing the macrocycles, wells containing 0.1% Triton X-100, wells containing a chemo cocktail comprised of 1 μ M Velcade, 100 μ M Etoposide and 20 μ M Taxol and wells containing no cells. Plates were incubated for 4 hours at 37°C in humidified 5% CO₂ atmosphere.

[00254] Towards the end of the 4 hour incubation time, 22 μ l FBS was added to each well for a total concentration of 10% FBS. After addition of serum, the plates were incubated for an additional 44 hours at 37°C in humidified 5% CO₂ atmosphere. At the end of the incubation period, MTT assay was performed according to manufacturer's instructions (Sigma, catalog #M2128) and absorbance was measured at 560nm using Dynex Opsys MR Plate reader.

Example 4. Melting temperature (T_m) Determination:

[00255] Lyophilized peptidomimetic macrocycle is dissolved in ddH₂O or 5% PEG-400 in 50 mM Tris, pH 7.4 to a final concentration of 25-50 μ M. Circular dichroism (CD) spectra are obtained with a Jasco-810 spectropolarimeter using standard measurement parameters (e.g. temperature, 10 or 20°C; wavelength, 190-260 nm; step resolution, 0.5

nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm). The α -helical content of each peptide is calculated by dividing the mean residue ellipticity (e.g. $[\Phi]_{222\text{obs}}$) by the reported value for a model helical decapeptide (Yang *et al.* (1986), *Methods Enzymol.* 130:208)). T_m is determined by measuring the circular dichroism (CD) spectra in a Jasco-810 spectropolarimeter at a fixed wavelength of 222 nm between the temperatures of 5-95°C. The following parameters are used for the measurement: data pitch, 0.1°C; bandwidth, 1nm and path length, 0.1cm averaging the signal for 16 seconds.

Example 5. Sample Preparation for Plasma Stability Determination:

[00256] For ex-vivo plasma stability studies 10 μM of peptidomimetic macrocycles are incubated with pre-cleared human and mouse plasma at 37°C for 0, 15 and 120 minutes. At the end of each incubation time, 100 μL of sample is removed, placed in a fresh low retention eppendorf tube with 300 μL of ice cold MECH. The samples are centrifuged at 10,000 rpm, the supernatant removed and placed in a fresh low retention eppendorf tube and 200 μL of HPLC H₂O was added to each sample. Samples are then analyzed by LC-MS/MS as indicated below.

Example 6. Protease Stability Assays:

[00257] For pepsin testing, each pair consisting of parent peptidomimetic macrocycle and α,α -methyl di-substituted peptidomimetic macrocycle sequences was combined (5 μM each) with positive control linear peptide (5 μM) in a safflower oil/ ethanol/ water suspension, 0.2 : 9.8 : 90, v/v(%), buffered (pH 1.8) with 0.015M HCl and 0.15 M NaCl. Eleven pairs were tested in eleven working solutions, each of which was aliquoted into 5 x 0.5 ml reaction volumes for pepsin incubation times of 10, 30, 45, 60 min, and a 0 min control with no pepsin added that was incubated for 60 min. The reaction was initiated at 38- 40°C by adding 20 μL of pepsin-silica gel slurry (0.4 μg pepsin) and shaking vials continually during subsequent incubation in 40°C oven. At each time point, the reaction was stopped by addition of 500 μL of 48:48:2 v/v(%) hexafluoro-2-propanol/ acetonitrile/ TFA. A biphasic mixture formed after mixing and the bottom layer liquid was subsequently injected in duplicate for LC/MS analyses in MRM detection mode. The reaction rate for each peptide was calculated in Excel as (-1) times the slope derived by a linear fit of the natural logarithm of uncalibrated MRM response versus enzyme incubation time. The reaction half-life for each peptide was calculated as $\ln 2 / \text{rate constant}$.

[00258] A similar procedure was used for trypsin testing. Each pair consisting of parent peptidomimetic macrocycle and α,α -methyl di-substituted peptidomimetic macrocycle sequences was combined (5 μM each) with linear peptide (5 μM) in a safflower oil/ ethanol/ water suspension, 0.2 : 9.8 : 90, v/v(%), buffered (pH7.8) with 0.055 M Tris-acetate, 0.15M NaCl. Ten pairs were tested in ten working solutions, each of which was aliquoted into 5 x 0.5 ml reaction volumes for trypsin incubation times of 10, 20, 30, 60 min, and a 0 min -no trypsin added control that was incubated for 60 min. The reaction was initiated at 38- 40°C by adding 20 μL of trypsin-silica gel slurry (0.4 μg or 0.32 μg trypsin) and shaking vials continually during subsequent incubation in 40°C oven. At each time point, the reaction was stopped by addition of 500 μL of 48:48:2 v/v(%) hexafluoro-2-propanol/ acetonitrile/ TFA. A biphasic mixture formed after mixing and the bottom layer liquid was subsequently injected in duplicate for LC/MS analyses in MRM detection mode. The reaction rate for each peptide was calculated in Excel as (-1) times the slope derived by a linear fit of the natural logarithm of uncalibrated MRM response versus enzyme incubation time. The reaction half-life for each peptide was calculated as $\ln 2 / \text{rate constant}$.

[00259] For Cathepsin D testing, each pair consisting of parent and α,α -methyl di-substituted cross-linked peptide (24 μM each) was combined with thirteen control cross-linked peptides in 75 mM ammonium acetate solutions pH 4.7

containing 125 mM KCl and 0.1% polysorbate 80 and aliquoted into 8 x 0.25 mL. Reaction was initiated at 38-40 °C by addition of 0, 1.0, 2.1 µg of cathepsin D for E/S ratios of 1:180 and 1:90 (w/w) to yield replicates of each mixture. After 240 minutes, the reaction was stopped by adding 200 µL of 49:49:2 v/v(%) hexafluoro-2-propanol/ acetonitrile/ TFA. A biphasic mixture formed after mixing and the bottom layer was subsequently diluted 1:10 in 1:1 v/v hexafluoro-2-propanol/acetonitrile. The resulting mixtures were analyzed by a gradient-LC /MS method that produced a characteristic LC retention time and molecular ion for each peptide. The apparent reaction rate for each peptide was calculated in Excel as (-1) times the slope derived by a linear fit of the natural logarithm of un-calibrated MS response versus enzyme / substrate ratio. The reaction half-life for each peptide was calculated as $\ln 2 / \text{rate constant}$. Control mixtures (no protease added) appeared stable (>60 min) in buffers containing safflower oil/ethanol/water suspension, 0.2 : 9.8 : 90, v/v(%), buffered with 0.015M HCl and containing 0.15M NaCl.

[00260] Results are shown in Figure 6. Improved stability to cathepsin D is observed for peptidomimetic macrocycles of the invention. Significant improvement in protease stability is obtained when an alpha,alpha-disubstituted amino acid is placed at the site of cleavage, while more distant placement of the alpha,alpha-disubstituted amino acid leads to somewhat reduced improvement in protease stability.

Example 7. Rat Mucosal Stability Assays:

[00261] Peptidomimetic macrocycles were divided between two mixtures to ensure unique molecular masses in each mixture containing ten peptides (4 µM each) 0.1% Tween 80, PBS, pH 7.0. GI Mucosal scrapings from 2 rats were suspended in 1 mL of PBS with 0.1% Tween 80, on wet ice and homogenized in a bead mill for 20 sec, yielding a homogeneous dispersion of ~0.7 g/ml tissue. The mucosal homogenate and peptide mixtures were combined 1:1 by volumes and vortexed for 1 min. The final concentration was 2 µM of each peptide. Incubation in a water bath was at 38 – 40 °C and 100 µl aliquots were taken after 0, 5, 10, 15, 20, 30, and 60 min time and immediately frozen. Peptide mixtures without added mucosal remained in water bath for 60 min. The peptides and metabolism products were extracted from the mixtures with 48:48:2 v/v(%) hexafluoro-2-propanol/ acetonitrile/trifluoroacetic acid and the organic (bottom) layers were directly injected for gradient-LC/MS analyses. Reconstructed ion chromatograms were made for predicted molecular ion masses corresponding to the intact peptides and to likely metabolites resulting from N and C – terminus truncation of each peptide. Because peptidomimetic macrocycles eluted in gradient times where little or no interferences were observed, reconstructed chromatograms for all predicted metabolites showed minimal or no deviations in baseline absent incubation time at 37°C. Uncalibrated chromatographic peak areas were obtained at each incubation time for each peptide and predicted truncation products and were normalized to yield 100% for a maximum peak area response and 0% for no peak area response. The responses were plotted versus incubation time in GraphPad.

[00262] Results are shown in Figure 8, which illustrates the increase in stability of peptidomimetic macrocycles of the invention to rat gastrointestinal mucosal peptidases.

Example 8. Cathepsin Proteolysis Product Determination:

[00263] For identification of Cathepsin B, D, and L metabolism, parent cross-linked peptide and positive control linear peptide (4 mM each in DMSO) was separately aliquoted (5 µL) to 1 mL volumes of 67 mM ammonium acetate solutions buffered either to pH 5.4 (cat B, L) and add 10 mM DTT, or to pH 4.4 (cat D) and add 0.117M KCl. Single enzyme working solution (10 µg/mL) was then added (40 µL) to each peptide solution (20µM) to yield initial weight ratio (%) of 1:20 for each enzyme and peptide pair. Each mixture was placed in a 38- 40°C oven for incubation times of 30 and 60 min. At each time point, the reaction was stopped by addition of 500µl of 48:48:2 v/v(%) hexafluoro-2-

propanol/ acetonitrile/ TFA. A biphasic mixture formed after mixing and the bottom layer liquid was diluted (1:10) into acetonitrile: water and subsequently injected in duplicate for gradient LC/ Ion Mobility TOF-MS analyses.

Example 9. Ion mobility-MS and MS-MS analysis and peptide sequencing:

[00264] Ion mobility-MS and MS-MS analysis and peptide sequencing were performed on a Waters (Milford, MA) Synapt high-resolution ion-mobility-time-of flight mass spectrometer. Samples were prepared by dilution of the unpurified cross-linked peptide proteolysis product samples 10-fold into 1:1 acetonitrile-water containing 0.1% formic acid. LC-MS analyses were performed by reverse-phase gradient elution with 0.1% formic acid and 0.1% formic acid in acetonitrile as eluants at 500 μ L/min. Electrospray ionization was performed from a nebulized capillary at 3.5 kV with a desolvation temperature of 200 °C and with 30V cone and 1.8 V skimmer (extraction lens) settings. Ion mobility separations of the multiply-charged proteolysis fragments from singly-charges background was performed as described in *Ion mobility-mass spectrometry*. Kanu, A.B., P. Dwivedi, M. Tam, L. Matz, and H.H. Hill, Jr., *J Mass Spectrom*, 2008. **43**(1): p. 1-22.

[00265] Results are shown in Figures 3-5. Figure 3 shows cleavage of SP-1 peptidomimetic macrocycle by cathepsin-D at F-Y residues. Figure 4 illustrates cleavage of SP-1 peptidomimetic macrocycle by Cathepsin-B at R-NH₂ to R-OH. Figure 5 shows degradation of SP-1 peptidomimetic macrocycle by cathepsin-L from the C-terminus of the peptidomimetic macrocycle.

[00266] Results with rat gastrointestinal mucosal peptidases are shown in Figure 7. Such peptidases are observed to degrade the peptide from the C-terminus inwards.

[00267] Nomenclature for the cleavage products is as follows: Product 0 is obtained by proteolysis of the C-terminal carboxamide, Product 1 is obtained by proteolysis of the amide bond between amino acids 1 and 2, Product 2 is obtained by proteolysis of the amide bond between amino acids 2 and 3, Product 3 is obtained by proteolysis of the amide bond between amino acids 3 and 4, Product 4 is obtained by proteolysis of the amide bond between amino acids 4 and 5, Product 5 is obtained by proteolysis of the amide bond between amino acids 5 and 6, and Product 6 is obtained by proteolysis of the amide bond between amino acids 6 and 7.

[00268] Peptide fragmentation was achieved using 35-45V Trap voltage with Argon as the collision gas. The MS-MS spectrum was deconvoluted to the singly-charged species using the Masslynx MaxEnt3 algorithm. Sequencing was performed with Waters BioLynx software, substituting the stapled macrocycle MW for a residue that is not present in the sequence.

Example 10. Cellular penetrability assays by FACS intracellular detection of FITC/FAM-labeled peptidomimetic macrocycles.

[00269] Jurkat cells or SJSA-1 cells were cultured with RPMI-1640 (Gibco, Cat#72400) plus 10% FBS (Gibco, Cat#16140) and 1% Penicillin + Streptomycin (Hyclone, Cat# 30010) at 37°C in a humidified 5% CO₂ atmosphere. Jurkat cells were split at 1x10⁶/ml or 0.5x10⁶/ml cell density, or SJSA-1 cells were seeded at 2x10⁵/ml/well in 24 well plates a day prior to the initiation of the study. The next day, cells were washed twice in Opti-MEM media (Gibco, Cat#51985) with spinning at 1200rpm, 23°C for 5min. The Jurkat cells were seeded in 0.9 ml of Opti-MEM in absence of serum or in 0.9 ml of Opti-MEM containing 1% human serum at density of 1x10⁶ cells in 24 well plates. The SJSA-1 cells were fed with 0.9ml of Opti-MEM in absence of serum in each well. Peptides were diluted to 2 mM stock in DMSO, followed by dilution to 400 μ M in sterile water; further dilution to 100 μ M was done using serum-free OPTI-MEM or Opti-MEM containing 1% human serum; same dilutions were made for DMSO controls. Thus 100 μ l of 100

μ M peptide working solution or final diluted DMSO were then added into appropriate wells to achieve peptide final concentration of 10 μ M or 2.5 μ M and the DMSO concentration 0.5% or 0.125% in 1 ml volume. Plates were incubated at 37°C incubator with 5%CO₂, or 4°C on wet ice for 1 hour or 4 hours. At the end of each time point, the cell suspension were diluted with RPMI-1640 plus 10% FBS and washed twice with 1XPBS (Gibco) plus 0.5% BSA and subjected to 0.25% Trypsin-EDTA (Gibco, Cat#25200) for 15 min or 8 min at 37°C. Cells were then washed with 1ml of RPMI-1640 plus 10% FBS and twice with 0.5 ml of 1XPBS plus 0.5% BSA (Sigma, Cat#A7906), spinning at 4000rpm, 4°C for 5 min (Eppendorf Centrifuge 5415D). Cells were suspended in 0.5 ml or 1 mL of 1XPBS plus 0.5%BSA. The Fluorescence or FAM intensity was measured by FACSCalibur, (BD Biosciences) or Guava Easy Cyte Plus, (Millipore). FACS data were analyzed with Flowjo software (BD Biosciences), and the data were graphed with Prism software. All assays were performed in duplicate.

Example 11. Intravenous Pharmacokinetic Analysis:

[00270] The IV dose formulation is prepared by dissolving peptide in 5 % DMSO/ D5W or 5% PEG-400 in 2% Dextrose to achieve a 10 or 3 mg/Kg dose. Canulated Crl:CD®(SD) male rats (7-8 weeks old, Charles River Laboratories) are used for intravenous doses at 10 mL/kg per single injection administered via the femoral cannula. SD male rats (7-8 weeks old, Charles River Laboratories) are used in these studies for 10 mL/kg intravenous doses at 3 mg/kg per single injection administered via tail vein injection. Blood for pharmacokinetic analysis is collected at 10 time points (0.0833, 0.167, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hrs post-dose). Animals are terminated (without necropsy) following their final sample collection.

[00271] The whole blood samples are centrifuged (~1500 x g) for 10 min at ~4 °C. Plasma is prepared and transferred within 30 min of blood collection/centrifugation to fresh tubes that are frozen and stored in the dark at ~-70 °C until they are prepared for LC-MS/MS analysis.

[00272] Sample extraction is achieved by adding 10 μ L of 50% formic acid to 100 μ L plasma (samples or stds), following by vortexing for 10 seconds. 500 μ L acetonitrile is added to the followed by vortexing for 2 minutes and centrifuged at 14,000rpm for 10 minutes at ~4°C. Supernatants are transferred to clean tubes and evaporated on turbovap <10 psi at 37°C. Prior to LC-MS/MS analysis samples are reconstituted with 100 μ L of 50:50 acetonitrile:water.

[00273] The peak plasma concentration (C_{max}), the time required to achieve the peak plasma concentration (t_{max}), the plasma terminal half-life ($t_{1/2}$), the area under the plasma concentration time curve (AUC), the clearance and volume of distribution are calculated from the plasma concentration data. All pharmacokinetic calculations are done using WinNonlin version 4.1 (Pharsight Corp) by non-compartmental analysis.

[00274] The following LC-MS/MS method is used. In brief, the LC-MS/MS instruments used was an API 365 (Applied Biosystems). The analytical column was a Phenomenex Synergi (4 μ , Polar-RP, 50mm x 2 mm) and mobile phases A (0.1 % formic acid in water) and B (0.1 % formic acid in methanol) are pumped at a flow rate of 0.4 ml/min to achieve the following gradient:

Time (min)	% B
0	15
0.5	15
1.5	95
4.5	95
4.6	15
8.0	Stop

MRM: 814.0 to 374.2 (positive ionization)

[00275] Example 12 . Mass spectroscopy-based assays for receptor binding assays.

[00276] Protein-ligand binding experiments for Bcl-x_L. Simple protein-ligand binding experiments were conducted using the following representative procedure outlined for a simple system-wide control experiment using 1 μ M SP-4 and 5 μ M Bcl-x_L. A 1 μ L DMSO aliquot of a 40 μ M stock solution of SP-4 is dissolved in 19 μ L of PBS (Phosphate-buffered saline: 50 mM, pH 7.5 Phosphate buffer containing 150 mM NaCl). The resulting solution is mixed by repeated pipetting and clarified by centrifugation at 10 000g for 10 min. To a 4 μ L aliquot of the resulting supernatant is added 4 μ L of 10 μ M BCL-x_L in PBS. Each 8.0 μ L experimental sample thus contains 40 pmol (1.5 μ g) of protein at 5.0 μ M concentration in PBS plus 1 μ M SP-4 and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated for 60 min at room temperature, and then chilled to 4 °C prior to size-exclusion chromatography-LC-MS analysis of 5.0 μ L injections. Samples containing a target protein, protein–ligand complexes, and unbound compounds are injected onto an SEC column, where the complexes are separated from non-binding component by a rapid SEC step. The SEC column eluate is monitored using UV detectors to confirm that the early-eluting protein fraction, which elutes in the void volume of the SEC column, is well resolved from unbound components that are retained on the column. After the peak containing the protein and protein–ligand complexes elutes from the primary UV detector, it enters a sample loop where it is excised from the flow stream of the SEC stage and transferred directly to the LC-MS via a valving mechanism. The (M + 3H)³⁺ ion of SP-4 is observed by ESI-MS at m/z 883.8, confirming the detection of the protein-ligand complex.

[00277] Example Protein-ligand K_d Titration Experiments for Bcl-x_L. Protein-ligand K_d titations experiments were conducted as follows: 2 μ L DMSO aliquots of a serially diluted stock solution of titrant peptidomimetic macrocycle (5, 2.5, ..., 0.098 mM) are prepared then dissolved in 38 μ L of PBS. The resulting solutions are mixed by repeated pipetting and clarified by centrifugation at 10 000g for 10 min. To 4.0 μ L aliquots of the resulting supernatants is added 4.0 μ L of 10 μ M BCL-x_L in PBS. Each 8.0 μ L experimental sample thus contains 40 pmol (1.5 μ g) of protein at 5.0 μ M concentration in PBS, varying concentrations (125, 62.5, ..., 0.24 μ M) of the titrant peptide, and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 30 min, then chilled to 4 °C prior to SEC-LC-MS analysis of 2.0 μ L injections. The (M + H)¹⁺, (M + 2H)²⁺, (M + 3H)³⁺, and/or (M + Na)¹⁺ ion is observed by ESI-MS; extracted ion chromatograms are quantified, then fit to equations described in Annis et al, 2007, to derive the binding affinity K_d. Similar assays were performed for Mcl-1, and Bcl-2.

[00278] Competitive Binding Experiments for Bcl-x_L. A mixture ligands at 40 μ M per component is prepared by combining 2 μ L aliquots of 400 μ M stocks of each of the three compounds with 14 μ L of DMSO. Then, 1 μ L aliquots of this 40 μ M per component mixture are combined with 1 μ L DMSO aliquots of a serially diluted stock solution of titrant peptide (10, 5, 2.5, ..., 0.078 mM). These 2 μ L samples are dissolved in 38 μ L of PBS. The resulting solutions are mixed by repeated pipetting and clarified by centrifugation at 10 000g for 10 min. To 4.0 μ L aliquots of the resulting supernatants is added 4.0 μ L of 10 μ M BCL-x_L in PBS. Each 8.0 μ L experimental sample thus contains 40 pmol (1.5 μ g) of protein at 5.0 μ M concentration in PBS plus 0.5 μ M ligand, 2.5% DMSO, and varying concentrations (125, 62.5, ..., 1.95 μ M) of the titrant peptide. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 60 min, then chilled to 4°C prior to SEC-LC-MS analysis of 2.0 μ L injections. The (M + H)¹⁺, (M + 2H)²⁺, (M + 3H)³⁺, and/or (M + Na)¹⁺ ion for the titrant and each mixture component is observed by ESI-MS; extracted ion chromatograms then analyzed as described in Annis et al, 2004, to rank-order binding affinities of the mixture components. More detailed information on these and other methods is available in “*A General Technique to Rank Protein-Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures.*” Annis, D. A.; Nazef, N.; Chuang, C. C.; Scott, M. P.; Nash, H. M. *J. Am. Chem. Soc.* **2004**, 126, 15495-15503 and “*ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions*” D. A. Annis, C.-C. Chuang, and N. Nazef. In *Mass Spectrometry in Medicinal Chemistry*. Edited by Wanner K, Höfner G:Wiley-VCH; **2007**:121-184. Mannhold R, Kubinyi H, Folkers G (Series Editors): *Methods and Principles in Medicinal Chemistry*.

Example 13. HeLa Cell Metabolism Assays:

[00279] For HeLa cell testing, each pair consisting of α -methyl and α,α -methyl di-substituted peptidomimetic macrocycle sequences was separately added (2.5 μ M each) to a cell culture buffer (OptiMEM) with 2% human serum to prepare working solutions at 37°C. Each of these was aliquoted (2ml) for replacing OptiMEM media (2ml) in three wells of 6-well culture plates, in which HeLa cells had been growing in log-phase overnight to form a nearly confluent monolayer of approximately 1.5 million cells in the bottom of each well. The cells had been collected from a culture flask on the previous day without trypsin or other protease, with the aid of 2mM disodium ethylene diamine tetraacetate (Na₂EDTA) in a 10mM disodium phosphate saline (PBS) solution. Duplicate plates were filled with the working solutions under sterile conditions and returned to a humidified 5%CO₂ atmosphere at 37°C for an incubation period of two hours. After incubation, the working solutions were aspirated off and replaced by a solution of 2% TFA in water (0.25mL), sufficient to cover monolayer in each well. The cell monolayer in each well was loosened by scrapping and the entire contents of each well was aspirated into a pipet tip and transferred to a polypropylene vial. Extraction of the peptidomimetic macrocycle sequences was done by mixing the contents of each vial with 500 μ l of 48:48:2 v/v(%) hexafluoro-2-propanol/ acetonitrile. A biphasic mixture formed after vortexing and centrifugation and the bottom layer liquid was subsequently injected in duplicate for LC/MS analyses designed for detection of molecular ions corresponding to peptidase products.

[00280] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A method of preparing a polypeptide with optimized protease stability, the method comprising
 - (a) providing a parent polypeptide comprising a cross-linker connecting a first amino acid and a second amino acid of said polypeptide;
 - (b) identifying a first motif comprising a protease cleavage site within said polypeptide;
 - (c) replacing the first motif with a second motif comprising at least one α,α -disubstituted amino acid, thereby producing a modified polypeptide;
 - (d) measuring the proteolytic stability of the modified polypeptide; and
 - (e) selecting the modified polypeptide as a polypeptide with optimized protease stability if the modified polypeptide has higher proteolytic stability than the parent polypeptide.
2. A method of preparing a polypeptide with optimized protease stability, the method comprising
 - (a) providing a parent polypeptide comprising a first cross-linker connecting a first amino acid and a second amino acid of said polypeptide;
 - (b) identifying a first motif comprising a protease cleavage site within said polypeptide;
 - (c) replacing the first motif with a second motif comprising a third amino acid, wherein the third amino acid is connected by a second crosslinker to another amino acid within said polypeptide, thereby producing a modified polypeptide;
 - (d) measuring the proteolytic stability of the modified polypeptide; and
 - (e) selecting the modified polypeptide as a polypeptide with optimized protease stability if the modified polypeptide has higher proteolytic stability than the parent polypeptide.
3. The method of claim 1 or 2, wherein the first motif is identified outside the sequence spanned by the cross-linker connecting said first and second amino acids.
4. The method of claim 1 or 2, wherein the parent polypeptide comprises a helix.
5. The method of claim 1 or 2, wherein the parent polypeptide comprises an α -helix.
6. The method of claim 1 or 2, wherein the cross-linker of the parent polypeptide connects the alpha-carbons (or side chains) of said first amino acid and said second amino acid.
7. The method of claim 1 or 2, wherein the cross-linker connects a first amino acid and a second amino acid that are separated by three amino acids.
8. The method of claim 1 or 2, wherein the cross-linker connects a first amino acid and a second amino acid that are separated by six amino acids.

9. The method of claim 1 or 2, wherein the cross-linker spans from 1 turn to 5 turns of the alpha-helix.
10. The method of claim 1 or 2, wherein the parent polypeptide carries a net neutral or net positive charge at pH 7.4.
11. The method of claim 1 or 2, wherein at least one of the first and second amino acids connected by said cross-linker is an α,α -disubstituted amino acid.
12. The method of claim 1 or 2, wherein both the first and second amino acids connected by said cross-linker are α,α -disubstituted.
13. The method of claim 1 or 2, wherein the protease is an intracellular protease.
14. The method of claim 1 or 2, wherein the protease is an extracellular protease.
15. The method of claim 1 or 2, wherein the protease is present in the blood of a vertebrate.
16. The method of claim 1 or 2, wherein the protease is present in the mouth or digestive tract of a vertebrate.
17. The method of claim 1 or 2, wherein the protease is present in the lungs of a vertebrate.
18. The method of claim 1 or 2, wherein the protease is present in the nasal sinus of a vertebrate.
19. The method of claim 1 or 2, wherein the protease is present in the skin of a vertebrate.
20. The method of claim 1 or 2, wherein the protease is present in the eye of a vertebrate.
21. The method of claim 1 or 2, wherein the parent polypeptide provides a therapeutic effect.
22. The method of claim 1 or 2, wherein the parent polypeptide binds to an intracellular target.
23. The method of claim 2, wherein the third amino acid is connected by the second crosslinker to the first or second amino acid.
24. A modified polypeptide prepared according to the method of any of the preceding claims.
25. The modified polypeptide of claim 24, wherein the protease stability of the modified polypeptide is at least 5-fold greater than that of the corresponding parent polypeptide.
26. A method of treating or controlling a disorder associated with aberrant BCL-2 family member expression or activity, comprising administering an effective amount of a polypeptide according to any of the preceding claims to a subject in need thereof.
27. Use of a polypeptide according to any of the preceding claims in the manufacture of a medicament for treating or controlling a disorder associated with aberrant BCL-2 family member expression or activity.
28. A polypeptide with optimized protease stability, comprising:
 - (a) a cross-linker connecting a first amino acid and a second amino acid of said polypeptide;

(b) at least one α,α -disubstituted amino acid, wherein the polypeptide has higher proteolytic stability than a corresponding polypeptide which does not comprise said α,α -disubstituted amino acid and wherein the corresponding polypeptide comprises a motif comprising a protease cleavage site;

wherein the higher proteolytic stability is measured by incubating said polypeptide and said corresponding polypeptide with a protease for a period of time sufficient to induce proteolytic degradation and comparing the proteolytic stability of said polypeptide with the proteolytic stability of said corresponding polypeptide.

29. The polypeptide of claim 28, wherein the α,α -disubstituted amino acid is located at a position corresponding to the position of the protease cleavage site in the corresponding polypeptide.

30. A polypeptide with optimized protease stability, comprising:

(a) a cross-linker connecting a first amino acid and a second amino acid of said polypeptide;
(b) a third amino acid connected by a second crosslinker to another amino acid within said polypeptide, wherein the polypeptide has higher proteolytic stability than a corresponding polypeptide which does not comprise said third amino acid and wherein the corresponding polypeptide comprises a motif comprising a protease cleavage site;

wherein the higher proteolytic stability is measured by incubating said polypeptide and said corresponding polypeptide with a protease for a period of time sufficient to induce proteolytic degradation and comparing the proteolytic stability of said polypeptide with the proteolytic stability of said corresponding polypeptide.

31. The polypeptide of claim 30, wherein the third amino acid is located at a position corresponding to the position of the protease cleavage site in the corresponding polypeptide.

32. A polypeptide prepared by a method comprising the steps of:

(a) providing a parent polypeptide comprising a cross-linker connecting a first amino acid and a second amino acid of said polypeptide;
(b) identifying a first motif comprising a protease cleavage site within said polypeptide;
(c) replacing the first motif with a second motif comprising at least one α,α -disubstituted amino acid, thereby producing a modified polypeptide;
(d) measuring the proteolytic stability of the modified polypeptide; and
(e) selecting the modified polypeptide as a polypeptide with optimized protease stability if the modified polypeptide has higher proteolytic stability than the parent polypeptide.

33. A polypeptide prepared by a method comprising the steps of:

- (a) providing a parent polypeptide comprising a first cross-linker connecting a first amino acid and a second amino acid of said polypeptide;
- (b) identifying a first motif comprising a protease cleavage site within said polypeptide;
- (c) replacing the first motif with a second motif comprising a third amino acid, wherein the third amino acid is connected by a second crosslinker to another amino acid within said polypeptide, thereby producing a modified polypeptide;
- (d) measuring the proteolytic stability of the modified polypeptide; and
- (e) selecting the modified polypeptide as a polypeptide with optimized protease stability if the modified polypeptide has higher proteolytic stability than the parent polypeptide.

1/14

																							Exact M+H	M+2H	M+3H
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	2615.4473	1308.2275	872.4876
H-		W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	2417.3356	1209.1717	806.4504
H-			I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	2231.2563	1116.1321	744.4240
H-				A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	2118.1723	1059.5900	706.7293
H-					Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	2047.1352	1024.0715	683.0503
H-						A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	1919.0766	960.0422	640.3641
H-							L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-NH2	1848.0395	924.5236	616.6850
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-CH	1848.0395	924.5236	616.6850
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R		-CH	2460.3302	1230.6690	820.7819
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A			-CH	2304.2291	1152.6184	768.7482
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y				-CH	2233.1920	1117.0999	745.0692
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F					-CH	2070.1287	1035.5682	690.7148
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A						-CH	1923.0603	962.0340	641.6920
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N							-CH	1852.0232	926.5155	618.0129
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F								-CH	1737.9803	869.4940	579.9986
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$									-CH	1590.9119	795.9598	530.9758
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F					-CH	2070.1287	1035.5682	690.7148
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A						-CH	2070.1287	1035.5682	690.7148
H-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A						-CH	1881.0497	941.0288	627.6884
H-		W	I	A	Q	A	L	R														-CH	857.4997	429.2537	286.5051
Ac-	R	W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-CH	2616.4313	1308.7195	872.8156
H-		W	I	A	Q	A	L	R	\$	I	G	D	\$	F	N	A	F	Y	A	R	R	-CH	2418.3196	1209.6637	806.7784


FIG. 1

2/14


SP-1: Ac-RWIAQALR\$IGD\$FNAFYARR-NH₂
6 5 4 3 2 1 0

FIG. 2


3/14

**FIG. 3**


4/14

**FIG. 4**

5/14

**FIG. 5**

6/14

**FIG. 6**

7/14




FIG. 7






FIG. 8


9/14

**FIG. 9**


10/14

**FIG. 9**


11/14

**FIG. 11**



12/14

**FIG. 12**

13/14

**FIG. 13**

14/14

**FIG. 14**